|
(Click sector to view stock chart)
Biotechnology
Stock Charts
(Click stock symbol to view stock chart, Support, Resistance, Pivot, Option chain, Volume, P/E, High, Low, Close, Market Cap, Average Volume, Dividend, % Change, $ Change, R1, R2, S1, S2, Previous Close, RSI - MACD - Williams %R - Stochastics - PPO, CMF, ADX, Aroon and more.......)
REPLIGEN CORPORATION (RGEN)
Repligen Corporation develops novel therapeutics for the treatment of diseases of the central nervous system. It sells Protein A products, which are used in the production of monoclonal antibodies and SecreFlo, a synthetic form of the hormone secretin, which is used as an aid in the diagnosis of certain pancreatic disorders. The company sells Protein A products to chromatography companies, diagnostics companies, biopharmaceutical companies, and laboratory researchers primarily through value-added resellers and distributors in the United States and internationally. It markets SecreFlo directly to gastroenterologists in the United States. The company also conducts drug development programs for diseases, such as schizophrenia, obsessive-compulsive disorder, bipolar disorder, and neurodegeneration. Repligen has a development agreement with the Stanley Medical Research Institute for a Phase 2 clinical trial of uridine in bipolar depression. The company was founded in 1981 and is based in Waltham, Massachusetts.
BIOMARIN PHARMACEUTICAL INC (BMRN)
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of biopharmaceuticals and therapeutics for serious diseases and medical conditions. Its product portfolio comprises three approved products and various investigational product candidates. The company offers Aldurazyme, an enzyme replacement therapy for the treatment of mucopolysaccharidosis I, a progressive and debilitating life-threatening genetic disease that frequently results in death during childhood or early adulthood; Naglazyme, an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI, an inherited, life-threatening lysosomal storage disorder; and Orapred, a drug primarily used to treat asthma exacerbations in children and other inflammatory conditions. BioMarin is also developing additional proprietary formulations of Orapred, including Orapred ODT (orally disintegrating tablets), which is under U.S. FDA review. In addition, the company is developing various other product candidates, including Phenoptin, a proprietary synthetic oral form of tetrahydrobiopterin for the treatment of moderate to mild forms of phenylketonuria (PKU); Phenylase, a preclinical-stage enzyme substitution therapy for the treatment of the more severe form of PKU; and 6R-BH4 for vascular dysfunction. BioMarin has a joint venture, BioMarin/Genzyme LLC, with Genzyme Corporation for the development and commercialization of Aldurazyme, as well as a strategic business partnership with Daiichi Suntory Pharma Co., Ltd. and Serono for Phenoptin, Phenylase and 6R-BH4 for cardiovascular indications. The company was founded in 1996 and is headquartered in Novato, California.
ONYX PHARMACEUTICALS INC (ONXX)
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of small molecule drugs for the treatment of cancer. Its primary product includes sorafenib, a Phase III orally available signal transduction inhibitor, inhibits proliferation of cancer cells and angiogenesis. In addition, sorafenib inhibits VEGFR-2 and PDGFR-ß, two proteins involved in angiogenesis, and other proteins that might be implicated in cancer. The company also develops PD 332991, a Phase I clinical trial product, a small molecule cell cycle inhibitor targeting a cyclin-dependent kinase. Onyx Pharmaceuticals has collaboration agreement with Bayer Pharmaceuticals Corporation to discover, develop, and market compounds that inhibit the function, or modulate the activity, of the RAS signaling pathway to treat cancer and other diseases. The company was established in 1992 and is headquartered in Emeryville, California.
XenoPort, Inc. develops and markets applications to enhance bioavailability of drugs. The company's product Transported Prodrug uses transporter genomics, assay technology, and proprietary chemistries to introduce therapeutic molecules into cells. Additionally, it provides solution to improve expiring drugs. XenoPort was founded in 1999 and is headquartered in Santa Clara, California.
Illumina, Inc. engages in the development and marketing of tools for the large-scale analysis of genetic variation and function. Its tools provide information used to improve drugs and therapies, customize diagnoses and treatment, and cure diseases. Its genotyping service product line combines the company's BeadArray technology with an automated, laboratory information management system controlled process to provide throughput identification of the common form of genetic variation, known as single nucleotide polymorphisms. The BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously. This technology includes the BeadArray Reader, GoldenGate assay protocols, laboratory information management system and analytical software, fluid-handling robotics, and access to Sentrix arrays and reagent kits for analyzing genetic sequences. Illumina offers Oligator technology for the parallel synthesis of various oligonucleotides for genomics applications. The company also provides DASL, a gene expression assay, for generating gene expression profiles from RNA samples, including those containing partially degraded RNAs. It offers SNP Genotyping, gene expression profiling, scanning instrumentation, and high-throughput synthesis. Illumina has a strategic collaboration with Invitrogen Corporation to synthesize and distribute oligos. The company markets and distributes its products to pharmaceutical, biotechnology, agrichemical, diagnostics, and consumer products companies, as well as to academic or private research centers in North America, Europe, Japan, Singapore, and the Pacific Rim countries. Illumina was founded by John R. Stuelpnagel and Mark Chee in 1998. The company is based in San Diego, California.
INCYTE CORPORATION (INCY)
Incyte Corporation engages in the discovery and development of small molecule drugs to treat medical conditions, including the infection with human immunodeficiency virus (HIV), inflammatory disorders, cancer, and diabetes. Its primary product candidate Reverset is a nucleoside analog reverse transcriptase inhibitor for use in combination with other antiviral drugs for patients with HIV infections, and is in phase IIb clinical trials. In addition, the company's drug discovery programs underway include CCR2 Receptor Antagonist Program and Sheddase Inhibitor Program. CCR2 Receptor Antagonist Program is focused on developing antagonists to a key chemokine receptor involved in inflammation called CCR2. CCR2 is a chemokine receptor found on monocytes that controls their migration into sites of inflammation. The primary products candidate form this program is in phase IIa clinical trial in patients with rheumatoid arthritis. The Sheddase Inhibitor Program involves sheddase inhibitors that would have application in the treatment of breast cancer and other tumor types and is in phase I clinical trials. The company markets its products in the United States and in Austria, Belgium, Canada, France, Denmark, Germany, Israel, Japan, the Netherlands, Sweden, Switzerland, and the United Kingdom. Incyte has collaborative agreement with Pharmasset, Inc.; Senomyx, Inc.; Genomic Health, Inc.; Pfizer, Inc.; and Medarex, Inc. Incyte was founded in 1991 and is headquartered in Wilmington, Delaware.
SEQUENOM, Inc., a genetics company, provides genetic analysis products that translate genomic science into superior solutions for biomedical research and molecular medicine. It primarily offers MassARRAY system that includes hardware, software, and consumable products. The MassARRAY system is a DNA analysis platform that measures the amount of genetic target material and variations therein. The system delivers data from biological samples and genetic target material that is available in trace amounts. The company offers its products primarily to pharmaceutical and biotechnology companies, laboratories, and governmental and other research institutions in North America, Europe, and Asia. It has strategic collaboration agreements with Bioscientia, Siemens Medical Solutions, and Procter & Gamble Pharmaceuticals. SEQUENOM was established in 1994 and is headquartered in San Diego, California.
SANGAMO BIOSCIENCES INC (SGMO)
Sangamo Biosciences, Inc. engages in the research, development, and commercialization of DNA binding proteins for the therapeutic regulation and modification of disease-associated genes. The company's gene regulation technology platform is enabled by the engineering of a class of transcription factors, known as zinc finger DNA-binding proteins (ZFPs). The applications of the company's technology include pharmaceutical discovery, development of human therapeutics, and plant agriculture. It has also initiated preclinical animal studies of ZFP therapeutics in congestive heart failure, nerve regeneration, and neuropathic pain; and has research-stage programs in human immunodeficiency virus, sickle cell anemia, X-linked severe combined immunodeficiency, Wiskott Aldrich Syndrome, age-related macular degeneration, and cancer immunotherapy. The company has strategic partnership with Edwards Lifesciences Corporation. Sangamo BioSciences has a research collaboration agreement with Pfizer, Inc. to develop cell lines for enhanced protein production. Sangamo Biosciences was founded in 1995 by Edward Lanphier. The company is headquartered in Richmond, California.
CHARLES RIVER LABORATORIES INTERNATIONAL INC (CRL)
Charles River Laboratories International, Inc. provides research tools and integrated support services that enable the drug discovery and development process. It operates in three segments: Research Models and Services (RMS), Preclinical Services, and Clinical Services. RMS segment produces and sells research models, primarily genetically and virally defined purpose-bred rats and mice. It also provides various related services that are designed to assist its customers in screening drug candidates. In addition, RMS offers transgenic services, laboratory services, consulting and staffing services, vaccine support, and in vitro technology services. Preclinical Services segment offers services in the areas, such as general and specialty toxicology, pathology, interventional and surgical, biopharmaceutical, pharmacokinetic and metabolic analysis, and bioanalytical chemistry. Clinical Services segment conducts Phase I clinical trials; and provides Phase II-IV clinical trials management services, which include testing, medical data sciences services, and regulatory support. Charles River Laboratories sells its products and services primarily through its direct sales force supplemented by a network of international distributors in the United States, Europe, and Japan. The company's customer base includes pharmaceutical, biotechnology, and animal health and medical device companies, as well as various government agencies, hospitals, and academic institutions. It operates approximately 100 facilities in 20 countries worldwide. Charles River Laboratories was founded in 1947 and is headquartered in Wilmington, Massachusetts.
CHELSEA THERAPEUTICS INTERNATIONAL LTD (CHTP)
Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses to acquire and develop products for the treatment of various human diseases. The company develops prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and cancer. It also develops therapeutic agent for the treatment of neurogenic orthostatic hypotension and related conditions, and diseases. In addition, the company develops platform technologies that consist of a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, and I-3D portfolio, a dihydroorotate dehydrogenase inhibiting compound. Chelsea Therapeutics' product in development includes CH-1504, an orally available molecule for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, psoriatic arthritis, and cancer. The company was incorporated in 2002 and is based in Charlotte, North Carolina.
SAVIENT PHARMACEUTICALS INC (SVNT)
Savient Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products that target unmet medical needs. It sells and distributes a generic version of oxandrolone, which is used to promote weight gain following involuntary weight loss related to disease or medical condition. The company also sells and distributes the branded version of oxandrolone in the United States, under the name Oxandrin. Further, Savient Pharmaceuticals is developing Puricase, which is in Phase III clinical studies for the control of elevated levels of uric acid in the blood or hyperuricemia. It distributes its products to drug wholesaler customers in the United States. The company was founded in 1980 as Bio-Technology General Corp. and changed its name to Savient Pharmaceuticals, Inc. in 2003. Savient Pharmaceuticals is headquartered in East Brunswick, New Jersey.
OBAGI MEDICAL PRODUCTS INC (OMPI)
Obagi Medical Products, Inc., a specialty pharmaceutical company, develops and markets skincare products in the United States and internationally. The company develops and commercializes prescription-based, topical skin health systems that enable physicians to treat a range of skin conditions, including pre-mature aging, photo-damage, hyper-pigmentation, and acne, as well as soft tissue deficits, such as fine lines and wrinkles. It offers Obagi Nu-Derm System, a prescription-based, topical skin health system on the market that has been shown to enhance the skin's overall health by correcting photo-damage at the cellular level; Obagi-C Rx System, a combination of prescription and OTC drugs and adjunctive cosmetic skin care products to treat skin conditions resulting from sun damage and the oxidative damage of free radicals; and Obagi Professional-C products, a line of proprietary, non-prescription products, which consist of Vitamin C serums used to reduce the appearance of damage to the skin caused by ultraviolet radiation and other environmental influences. The company also offers Nu-Derm Condition and Enhance System for use in conjunction with commonly performed cosmetic procedures including Botox injections, and ELASTIderm product line, an eye cream for improving the elasticity and skin tone around the eyes; and markets tretinoin, used for the topical treatment of acne in the United States, and Obagi Blue Peel products, used to aid the physician in the application of skin peeling actives. It sells its products through its own domestic sales force and foreign distribution partners to plastic surgeons, dermatologists, and other physicians that are focused on aesthetic and therapeutic skin care. The company was founded in 1988 and is headquartered in Long Beach, California.
MARTEK BIOSCIENCES CORPORATION (MATK)
Martek Biosciences Corporation engages in the development, manufacture, and sale of products derived from microalgae and other microbes primarily in the United States. Its products include nutritional oils used in infant formula, nutritional supplements, and food fortification ingredients, and fluorescent markers for diagnostics and rapid miniaturized screening. The company's nutritional oils consist of fatty acid components, such as docosahexaenoic acid (DHA) and arachidonic acid (ARA). DHA and ARA help in developing the eyes and central nervous systems of newborns, and DHA helps in promoting adult mental and cardiovascular health. It develops fluorescent detection products from microalgae that connect fluorescent algal proteins to antibodies. These products and technologies enable researchers in drug discovery and diagnostics. Fluorescent detection products include Phycobiliproteins, which are classical direct fluorescent detection dyes and SensiLight dyes that are used to match the sensitivity of chemiluminescent methods. Martek Biosciences markets and sells its nutritional oils primarily to the infant formula and natural products industries. The company has a collaborative agreement with SemBioSys Genetics, Inc., a Canadian biotechnology company, to co-develop plant-based DHA products. Martek Biosciences was founded by Radmer in 1985. The company is based in Columbia, Maryland.
Clinical Data, Inc. offers clinical chemistry and hematology laboratory instrumentation, diagnostic assays, and consulting services for the physician office laboratory (POL), clinics, and smaller hospitals worldwide. The company principally operates through three subsidiaries located in the United States, Netherlands, and Australia. The company's United States subsidiary, Clinical Data Sales & Service, Inc., supplies various products and services, including equipment and reagents, lab management, and consulting services, to the POLs and small and medium sized medical laboratories in the United States. The company's Dutch subsidiary, Vital Scientific NV, designs and manufactures scientific instrumentation marketed worldwide through distributors and strategic partnerships. The company's Australian subsidiary, Vital Diagnostics Pty., Ltd., distributes diagnostic instruments and assays in the south Pacific region. The company provides private labeled blood chemistry analyzers, ESR automated analyzers, diagnostic assays, and consumables, as well as technical support. In addition, it also provides a laboratory information software system for the management and control of smaller laboratories. The company's products are primarily sold through a network of distributors, as well as through dealers and also directly to the end customer. Clinical Data has a collaborative research agreement with the University of Pittsburgh Cancer Institute for metabolomics analysis of lung cancer samples. The company, formerly known as Novitron International, Inc., was founded in 1969 and is headquartered in Newton, Massachusetts.
GILEAD SCIENCES INC (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for patients suffering from life-threatening diseases primarily in North America, Europe, and Australia. It focuses its research and clinical programs on anti-infectives. The company's products include Viread, Emtriva, and Truvada, which are used for the treatment of human immunodeficiency virus infection in adults; AmBisome, an antifungal agent to treat serious invasive fungal infections caused by various fungal species; Hepsera, which is used for the treatment of chronic hepatitis B infection; Vistide, used for the treatment of cytomegalovirus retinitis; and DaunoXome, a liposomal formulation of the anticancer agent daunorubicin, for the treatment of AIDS-related Kaposi's sarcoma. Its products also comprise Tamiflu, which is used for the prevention and treatment of influenza; and Macugen, for the treatment of neovascular age-related macular degeneration. Gilead sells its products primarily through wholesalers and distributors. The company has collaborative relationships with Bristol-Myers Squibb Company; Achillion Pharmaceuticals, Inc.; EyeTech Pharmaceuticals, Inc.; Fujisawa Healthcare, Inc.; GlaxoSmithKline; Japan Tobacco, Inc.; Pfizer, Inc.; F. Hoffmann-La Roche, Ltd.; and Sumitomo Pharmaceuticals Co., Ltd. Gilead was founded by Michael Riordan in 1987. The company is headquartered in Foster City, California.
IDERA PHARMACEUTICALS INC (IDRA)
Idera Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, asthma/allergies, and for use as vaccine adjuvants. It designs proprietary product candidates that are designed to modulate immune responses through Toll-like Receptors, the body's first line of immune defense. The company's DNA chemistry enables it to identify product candidates for the internal development programs and creates opportunities for multiple collaborative alliances. Its drug candidates include IMO-2055, an agonist of TLR9, which is in Phase II trial for renal cell carcinoma; and IMO-2125, a lead product candidate for treating infectious diseases. The company is collaborating with Merck & Co., Inc. to research, develop, and commercialize vaccine products containing its TLR7, 8, or 9 agonists in the fields of oncology, infectious diseases, and Alzheimer's disease. It is also collaborating with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies. Idera Pharmaceuticals was founded in 1989. The company was formerly known as Hybridon, Inc. and changed its name to Idera Pharmaceuticals, Inc. in 2005. Idera Pharmaceuticals is based in Cambridge, Massachusetts.
IGI LABORATORIES INC (IG)
IGI, Inc. engages in the production and marketing of cosmetics and skin care products primarily in the United Stares. The company, through its licensed Novasome microencapsulation technologies, engages in the contract manufacture of various dermatological, consumer, skin care, and hair care products. It produces Novasome vesicles for various skin care products. Novasome lipid vesicles are used to encapsulate skin protective agents, oils, moisturizers, shampoos, conditioners, skin cleansers, and fragrances for cosmetics and consumer product applications. IGI also sublicenses the technologies to other companies. In addition, it engages in metal finishing business. The company was incorporated in 1977 and is headquartered in Buena, New Jersey.
QIAGEN N.V., through its subsidiaries, provides enabling technologies and products for the separation, purification, and handling of nucleic acids and proteins. It offers a portfolio of consumable products for nucleic acid and protein separation, purification and handling, and nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products, and related services. Its consumable products applications include plasmid deoxyribonucleic (DNA) acid purification; ribonucleic acid (RNA) stabilization and purification; genomic and viral nucleic acid purification; nucleic acid transfection; PCR amplification; reverse transcription; DNA cleanup after PCR and sequencing; DNA cloning and protein purification. Its BioRobot systems offer automation of nucleic acid preparation in low, medium, or high throughput scale, as well as reaction set-up and other laboratory tasks. The company also offers custom services, small interfering RNA synthesis, whole genome amplification services, DNA sequencing, and noncGMP and cGMP DNA production on a contract basis. The company sells its products to academic research markets, and pharmaceutical and biotechnology companies, as well as developing commercial markets, including applied testing markets, clinical research, nucleic acid-based molecular diagnostics, and genetic vaccination, and gene therapy. It operates in the United States, Germany, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, Sweden, and the Netherlands. QIAGEN has a strategic alliance with Eppendorf AG to co-develop and co-market complementary and optimized products. The company was co-founded in 1984 by Detlev H. Riesner and Metin Colpan. QIAGEN is headquartered in Venlo, The Netherlands.
CORCEPT THERAPEUTICS INCORPORATED (CORT)
Corcept Therapeutics Incorporated, a development stage biopharmaceutical company, engages in the development of drugs for the treatment of severe psychiatric and neurological diseases. The company develops CORLUX for the treatment of the psychotic features of psychotic major depression, which is in Phase III clinical trials. Corcept Therapeutics Incorporated was co-founded by Alan Schatzberg and Joseph K. Belanoff. The company was incorporated in 1998 and is based in Menlo Park, California.
OSI PHARMACEUTICALS INC (OSIP)
OSI Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of oncology products for cancer patients in the United States. Its flagship product, Tarceva, is an oral, once-a-day, small molecule inhibitor of the epidermal growth factor receptor. The company also markets Novantrone for the approved oncology indications; and Gelclair for the relief of pain associated with oral mucositis. Its other drug candidates include OSI-7904L, a liposomal formulation of a potent thymidylate synthase inhibitor, which is in phase II study; OSI-461, an inhibitor of cGMP phosphodiesterases, which is in phase I dose optimization study; and OSI-930, a tyrosine kinase inhibitor, which is in preclinical research stage. In addition, OSI Pharmaceuticals, through its collaborative drug discovery program, develops CP-547,632, which targets vascular endothelial growth factor receptor and is in Phase II and Phase I trials; CP-868,596 that targets tumor derived angiogenesis and is in Phase I trials; and CP-724,714, which is an oral inhibitor of epidermal growth factor receptor 2 and is in Phase I clinical trial. Further, its subsidiary, Prosidion Limited, specializes in diabetes and obesity treatment in the United Kingdom. The company has collaboration agreements with Pfizer, Inc.; Cold Spring Harbor Laboratory; EiRX Therapeutics plc; Genentech, Inc.; PR Pharmaceuticals, Inc.; and Roche. OSI Pharmaceuticals is headquartered in Melville, New York.
ALNYLAM PHARMACEUTICALS INC (ALNY)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on RNA interference (RNAi) in the United States. The company is developing a pipeline of RNAi products using Direct RNAi to treat ocular, central nervous system, and respiratory diseases; and Systemic RNAi to treat a range of diseases, including oncology, metabolic, and autoimmune diseases. Its RNAi development programs are focused on an eye disease, known as age-related macular degeneration; and on a lung infection caused by a virus, known as human respiratory syncytial virus. The company also has multiple preclinical programs in Direct RNAi focused on a central nervous system disorder, known as Parkinson's disease; spinal cord injury; and a genetic disease, known as cystic fibrosis. In addition, Alnylam offers nontherapeutic license agreements to life science reagent and service providers. The company has strategic alliances and research collaborations with Merck & Co., Inc.; Medtronic, Inc.; Cystic Fibrosis Foundation Therapeutics, Inc.; Mayo Foundation for Medical Education and Research; Novartis AG; and Mayo Clinic Jacksonville. Alnylam was founded by Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore in 2002. The company is headquartered in Cambridge, Massachusetts.
ACORDA THERAPEUTICS INC (ACOR)
Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States. It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The company's lead product candidate is Fampridine-SR, which is in a Phase III clinical trial for the improvement of walking ability in people with multiple sclerosis. Its preclinical programs comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in MS, Glial Growth Factor 2, or GGF-2, and remyelinating antibodies; and Chondroitinase Program that develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through internal specialty sales force and contract pharmaceutical telesales organizations. The company was founded in 1995 and is based in Hawthorne, New York.
GENZYME CORPORATION (GENZ)
Genzyme Corporation operates as a biotechnology company. Its products and services focuses on rare genetic disorders, renal disease, kidney disease, cancer, orthopaedics, organ transplant, and diagnostic and predictive testing. The company operates in five segments: Renal, Therapeutics, Transplant, Biosurgery, and Diagnostics/Genetics. The Renal unit develops, manufactures, and distributes products that treat patients suffering from renal diseases, including chronic renal failure. The Therapeutics unit offers therapeutic products for genetic diseases; and other chronic debilitating diseases, including lysosomal storage disorders and other specialty therapeutics. The Transplant unit provides therapeutic products that address pretransplantation, prevention, and treatment of acute rejection in organ transplantation, as well as other auto-immune disorders. The Biosurgery unit develops, manufactures, and distributes biotherapeutics and biomaterial products, with an emphasis on products that meet medical needs in orthopaedics and broader surgical areas. The Diagnostics/Genetics unit offers vitro diagnostic products; and testing services for the oncology, and prenatal and reproductive markets. The company offers its products primarily to physicians, hospitals, and treatment centers in various countries, including the United States, the United Kingdom, Ireland, the Netherlands, Belgium, France, Canada, Switzerland, and Germany. Genzyme Corp. has an agreement with RenaMed Biologics, Inc. to jointly develop and commercialize RenaMed's Bio-Replacement Therapy for the treatment of acute renal failure; a collaboration with De Novo Pharmaceuticals, Ltd. to apply De Novo's molecular structure generating technology to focus on a disease target of interest to Genzyme; and a collaboration agreement with Epiontis GmbH to develop quality control tests for Genzyme's cartilage repair product Carticel. The company was founded in 1981 and is based in Cambridge, Massachusetts.
Curis, Inc., a therapeutic drug development company, focuses on the discovery and development of products that modulate key regulatory signaling pathways controlling the repair and regeneration of human tissues and organs. Its product development approach involves using small molecules, proteins, or antibodies to modulate these regulatory signaling pathways. Curis uses this product development approach to produce various drug product candidates in the fields of cancer, kidney disease, neurological disorders, hair growth, and cardiovascular disease. The company is developing its product candidate programs in various signaling pathways, including the Hedgehog and Bone Morphogenetic Protein pathways. Its lead product candidate is a topical therapy for the treatment of basal cell carcinoma and is under development in collaboration with Genentech, Inc. The company has strategic collaborations with Genentech and Wyeth Pharmaceuticals to develop therapeutics, which modulate the signaling of the Hedgehog pathway; an additional collaboration with Genentech to develop therapeutics that modulate an undisclosed signaling pathway that plays an important role in cell proliferation; and a research and development agreement with Procter & Gamble Pharmaceuticals U.K. Limited to evaluate and develop treatments for hair growth regulation utilizing Curis' Hedgehog agonist technology. Curis is headquartered in Cambridge, Massachusetts.
SINOVAC BIOTECH LTD (SVA)
Sinovac Biotech, Ltd. engages in the research, development, commercialization, and sale of human-use vaccines and related products for infectious diseases. It offers Healive, a vaccine for hepatitis A; Bilive, a combined vaccine for hepatitis A and B; and Anflu, a split flu vaccine. The company is also developing SARS vaccine, which is in phase I clinical trails, as well as has a co development agreement with the China Centre of Disease Control and Prevention for the development of Avian Flu-Pandemic Influenza Vaccine. Sinovac Biotech was founded in 1999 and is headquartered in Beijing, China.
REGENERON PHARMACEUTICALS INC (REGN)
Regeneron Pharmaceuticals, Inc. engages in the discovery and development of pharmaceutical products for the treatment of human disorders and conditions. Its clinical and preclinical pipeline includes product candidates for the treatment of cancer, diseases of the eye, rheumatoid arthritis, and other inflammatory conditions like allergies, asthma, and other diseases and disorders. The company primarily focuses on the development of the VEGF Trap in oncology and eye diseases, which are in phase I clinical trails; and the IL (Interleukin)-1 Trap in various indications in, which interleukin-1 plays a role, including rheumatoid arthritis and other inflammatory conditions. VEGF TRAP is a protein-based product candidate designed to bind Vascular Endothelial Growth Factor (VEGF) and the related Placental Growth Factor, and prevent their interaction with cell surface receptors. Interleukin-1 Trap, which is in preclinical stage, is a protein-based product candidate designed to bind the interleukin-1 cytokine and prevent its interaction with cell surface receptors used for the treatment of diseases associated with inflammation in blood vessels. IL-1 Trap is in phase 2b study for its use in rheumatoid arthritis in a double blind, placebo-controlled, and multicenter trial. Regeneron's product candidates in preclinical development stage include Interleukin-4/Interleukin-13 Trap, a protein-based product candidate designed to bind both the interleukin-4 and interleukin-13, which is used for the treatment of diseases, such as asthma, allergic disorders, and other inflammatory diseases. The company also provides contract manufacturing services for the production of an intermediate for a pediatric vaccine. Regeneron has collaboration and licensing agreements with sanofi-aventis Group, Novartis Pharma AG, and The Procter & Gamble Company. The company was founded by Leonard S. Schleifer in 1988. Regeneron is headquartered in Tarrytown, New York.
COMBIMATRIX CORPORATION (CBMX)
Acacia Research Corporation - CombiMatrix engages in the development of technologies and products in the areas of drug development, genetic analysis, nanotechnology research, defense, and homeland security markets. Its platform technologies produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations, and proteins. The company's technology application areas include genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences, and nanotechnology. Its other technologies include molecular synthesis and screening methods for the discovery of potential new drugs. The company's products are designed to aid in the discovery and development of new drugs and diagnostics for human healthcare. It has collaboration with Novavax, Inc. to develop a technique for in-process monitoring of vaccine production. The company is headquartered in Mukilteo, Washington. Acacia Research Corporation - CombiMatrix operates as a division of Acacia Research Corporation.
SEATTLE GENETICS INC (SGEN)
Seattle Genetics, Inc. develops monoclonal antibody-based therapeutic products for the treatment of cancer and immunologic diseases. The company's monoclonal antibody-based technologies include genetically engineered monoclonal antibodies, antibody-drug conjugates (ADC), and antibody-directed enzyme prodrug therapy (ADEPT), which are used to develop monoclonal antibodies that can kill target cells on their own, as well as increase the potency of monoclonal antibodies. Its product candidate, SGN-30, is in phase II clinical trials, which is used for the treatment of Hodgkin's disease and systemic anaplastic large cell lymphoma; and SGN-15 has completed a phase II clinical trial for use in the treatment of nonsmall cell lung cancer. The company's SGN-40 is in phase I clinical trials in patients with multiple myeloma. In addition, it has four product candidates in preclinical development: SGN-35, SGN-70, SGN-75, and SGN-17/19. The company is conducting preclinical development tests of SGN-35 for the treatment of hematologic malignancies, such as Hodgkin's disease and some types of nonHodgkin's lymphoma. SGN-75 is an ADC composed of an anti-CD70 monoclonal antibody. The CD70 antigen is expressed on renal cancer, nasopharyngeal carcinoma, and certain hematologic malignancies. SGN-17/19, an ADEPT product candidate, is being developed for the treatment of metastatic melanoma. The company has collaboration agreements with Genentech, Celera Genomics Group, UCB Celltech, Protein Design Labs, PSMA Development Company LLC, CuraGen, and Bayer for its ADC technology; and with Genencor for its ADEPT technology. Seattle Genetics was co-founded in 1997 by H. Perry Fell and Clay B. Siegall. The company is headquartered in Bothell, Washington.
Biogen Idec, Inc. engages in the development, manufacture, and commercialization of novel therapies worldwide. It offers AVONEX, RITUXAN, TYSABRI, ZEVALIN, and AMEVIVE products. The company's AVONEX is approved for the treatment of relapsing forms of multiple sclerosis; RITUXAN is used in the treatment of certain B-cell non-Hodgkin's lymphomas (NHL) or B-cell NHLs; TYSABRI is approved to treat relapsing forms of MS to reduce the frequency of clinical relapses; ZEVALIN used in the treatment of cancer; and AMEVIVE treats adult patients with moderate-to-severe chronic plaque psoriasis. Biogen Idec has collaborations with Genentech, Inc.; Vernalis plc; Elan Corporation, plc; Fumapharm AG; ImmunoGen, Inc.; Sunesis Pharmaceuticals, Inc.; Cellectis SA; and Zenyaku Kogyo Co., Ltd. The company was founded in 1985. It was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec, Inc. in 2003. Biogen Idec is headquartered in Cambridge, Massachusetts.
ENZON PHARMACEUTICALS INC (ENZN)
Enzon Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of human therapeutics for life threatening diseases. The company markets four human therapeutic products, such as ABELCET, ONCASPAR, ADAGEN, and DEPOCYT. ABELCET is a lipid complex formulation of amphotericin B used primarily in the hospital to treat immuno-compromised patients with invasive fungal infections. ONCASPAR is a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase. It is approved in the United States, Canada, and Germany; and is used in conjunction with other chemotherapeutics to treat patients with acute lymphoblastic leukemia who are hypersensitive or allergic to native or unmodified forms of L-asparaginase. ADAGEN is used to treat patients afflicted with a type of severe combined immunodeficiency disease, also known as the ‘Bubble Boy' disease, which is caused by the chronic deficiency of the adenosine deaminase enzyme. DEPOCYT is an injectable chemotherapeutic approved for the treatment of patients with lymphomatous meningitis. The company also develops PEG-INTRON, which is used in combination with REBETOL for the treatment of chronic hepatitis C; and ATG FRESENIUS S, a polyclonal antibody preparation that is used for T-lymphocyte suppression in organ transplant patients in order to prevent organ graft rejection. The company has strategic alliances with Nektar Therapeutics, SkyePharma, PLC, and Inex Pharmaceuticals Corporation. Enzon Pharmaceuticals was incorporated in 1981 and is headquartered in Bridgewater, New Jersey.
TECHNE CORPORATION (TECH)
TECHNE Corporation, through its subsidiaries, engages in the development and manufacture of biotechnology products and hematology calibrators and controls. The company operates in two divisions, Biotechnology and Hematology. The Biotechnology division engages in the development and manufacture of cytokines and enzymes, antibodies, assay kits, clinical diagnostic kits, flow cytometry products, and intracellular cell signaling products. These products are sold to biomedical researchers and clinical research laboratories. The Hematology division develops and manufactures whole blood hematology controls and calibrators, linearity and reportable range controls, whole blood reticulocyte controls, whole blood flow cytometry controls, whole blood glucose/hemoglobin control, erythrocyte sedimentation rate control, and multipurpose platelet reference controls. These products are sold to hospitals and clinical laboratories to check the performance of hematology instruments. In addition, the company distributes biotechnology products in Europe. The company was founded in 1976 and is based in Minneapolis, Minnesota.
XOMA, Ltd., a biopharmaceutical company, engages in the development and manufacture of antibodies and other genetically-engineered protein products to treat immunological and inflammatory disorders, cancer, and infectious diseases. The company's proprietary and collaborative product development programs include RAPTIVA, a humanized therapeutic monoclonal antibody, for the treatment of adults for moderate to severe plaque psoriasis; CHIR-12.12, an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies; and NEUPREX, a Phase II clinical trial product, IV formulation of rBPI21, a modified recombinant fragment of bactericidal/permeability-increasing protein for multiple anti-infective and antiendotoxin indications. Its development products also comprise MLN2222, a Phase II clinical trial product, a complement inhibitor under development to reduce the incidence of complications in patients undergoing surgical procedures involving the use of cardiopulmonary bypass; Gastrin, a preclinical antigastrin antibody, for Gastric cancers; ING-1, a Phase I clinical trial product, Human Engineered antibody to Ep-CAM for Adenocarcinomas; and XMP.629, a topical formulation of BPI derived antimicrobial peptide fro acne. XOMA, Ltd. also licenses its proprietary technologies relating to bacterial expression of recombinant pharmaceutical products, as well as its Human Engineering technology that allows modification of any nonhuman monoclonal antibody to reduce or eliminate detectable immunogenicity in humans to biotechnology and pharmaceutical companies. It has collaboration and license agreements with Genentech, Inc.; Chiron Corporation; Zephyr Sciences, Inc.; Millennium Pharmaceuticals, Inc.; Aphton Corporation; Merck & Co., Inc.; Lexicon Genetics Incorporated; Cubist Pharmaceuticals, Inc.; and Triton BioSystems, Inc. The company was founded by Patrick J. Scannon. XOMA, Ltd. was incorporated in 1981 and is headquartered in Berkeley, California.
Cerus Corporation develops products for cancer, infectious disease, and blood safety. It develops cancer immunotherapies based on its Listeria vaccine platform combined with disease antigens. The company is also developing the INTERCEPT Blood System, which is based on the company's Helinx technology for controlling biological replication. The INTERCEPT Blood System is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, other pathogens, and white blood cells. This system targets and inactivates blood-borne pathogens, such as HIV and hepatitis B and C, as well as harmful white blood cells, while leaving the therapeutic properties of the blood components intact. Cerus is also developing a proprietary vaccine platform to stimulate the immune system to target and attack cancer cells and infectious diseases. The company has collaboration agreements with Baxter Healthcare Corporation and BioOne Corporation for the joint development of the INTERCEPT Blood System for platelets and plasma; and with MedImmune, Inc. to co-develop a therapeutic vaccine designed to treat cancers of the breast, prostate, and colon, as well as metastatic melanomas. Cerus was incorporated in 1991 and is based in Concord, California.
Antigenics, Inc., a biotechnology company, engages in the research and development of technology and products to treat cancers, infectious diseases, and autoimmune disorders. The company's principal product candidate, Oncophage, a personalized cancer vaccine, is in phase III clinical trials for the treatment of renal cell carcinoma and for metastatic melanoma, as well as in phase I/II trial for lung cancer. Its product portfolio also includes AG-858, a personalized cancer vaccine in a phase II clinical trial for the treatment of chronic myelogenous leukemia; AG-702/AG-707, a therapeutic vaccine program in phase I clinical development for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for colorectal cancer and other solid tumors. The company was founded as Antigenics L.L.C. in 1994 and changed its name to Antigenics, Inc. in 2000. Antigenics is headquartered in New York City.
PONIARD PHARMACEUTICALS INC (PARD)
Poniard Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of cancer therapy products in the United States. Its lead product is Picoplatin, a platinum-based cancer therapy, designed to overcome platinum resistance in the treatment of solid tumors. Picoplatin is in Phase II clinical trails in small cell lung cancer and is in Phase I/II trials for colorectal and hormone-refractory prostate cancers. The company has a collaboration agreement with The Scripps Research Institute on the discovery of novel, small-molecule, and multi-targeted protein kinase inhibitors and focal adhesion kinase inhibitors as therapeutic agents, including for the treatment of cancer. Poniard Pharmaceuticals was founded in 1984. It was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in 2006. The company is headquartered in South San Francisco, California.
NPS PHARMACEUTICALS INC (NPSP)
NPS Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of small molecules and recombinant proteins. The company's product candidates are used primarily for the treatment of bone and mineral disorders, gastrointestinal disorders, and central nervous system disorders. NPS's products include PREOS, Calcilytic Compounds, Cinacalcet HCl, Teduglutide, mGluR5 Antagonists, Isovaleramide, Delucemine, Metabotropic Glutamate Receptors, and Glycine Reuptake Inhibitors. The PREOS and Calcilytic Compounds are in phase III and I stage respectively, which are used for the treatment of osteoporosis. The Cinacalcet HCl is in phase II stage, which is used for Hyperparathyroidism. The Teduglutide is in phase II stage and is used for short bowel syndrome or crohn's disease. The mGluR5 Antagonists is in the preclinical stage, which is for gastroesophageal reflux disease. The Isovaleramide is in phase II stage and is used for migraine. The Delucemine is in phase I stage that is used for depression. The Metabotropic Glutamate Receptors is in preclinical stage, which is used for psychiatric and neurologic disorders and pain. The Glycine Reuptake Inhibitors is in preclinical stage that is used for schizophrenia and dementia. The company has collaborative research, development, or license agreements with Amgen, Inc.; AstraZeneca AB; Janssen Pharmaceutical N.V; GlaxoSmithKline; Kirin Brewery, Ltd.; and Nycomed Danmark ApS. The company was founded in 1986 and is headquartered in Salt Lake City, Utah.
CADENCE PHARMACEUTICALS INC (CADX)
Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the in-licensing, development, and commercialization of product candidates principally for use in the hospital setting in the United States and Europe. It has two Phase III products in development, including IV APAP for the treatment of acute pain and fever; and Omigard for the prevention of intravascular catheter-related infections. Cadence Pharmaceuticals, formerly known as Strata Pharmaceuticals, Inc., was founded in 2004 and is headquartered in San Diego, California.
CYTORI THERAPEUTICS INC (CYTX)
Cytori Therapeutics, Inc. engages in developing and commercializing stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and serious, chronic, and life threatening conditions. The company develops various products that are in clinical testing stages, which include Celution System, a device that removes stem and regenerative cells from a patient's adipose tissue, as well as used in breast reconstruction applications; Celution PRS System that could be used in plastic and reconstructive surgeries; and Celution CV System for the treatment of chronic myocardial ischemia and heart attacks. Cytori Therapeutics also develops a Celution System, which is under preclinical stage, for investigative applications in gastrointestinal disorders, which could address fistulas and wounds associated with inflammatory disorders, such as Crohn's disease and intestinal repair; peripheral vascular disease; and orthopedic applications, such as bone and spinal disc repair. In addition, it operates a tissue bank facility for the preservation of stem and regenerative cells extracted from adipose tissue. Further, Cytori Therapeutics manufactures macropore biosurgery products that include HYDROSORB family of spine and orthopedic implant products; and thin film bioresorbable soft tissue separation implant products. It has strategic joint venture with Olympus Corporation to develop and manufacture future generation devices based on its Celution system. The company was founded in 1996. It was formerly known as MacroPore, Inc. and changed its name to MacroPore Biosurgery, Inc. Further, the company changed its name to Cytori Therapeutics, Inc. in 2005. Cytori Therapeutics is headquartered in San Diego, California.
ACADIA PHARMACEUTICALS INC (ACAD)
ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company has four drug programs in clinical development and in preclinical and discovery stages. Its three clinical programs are ACP-103 for treatment-induced dysfunctions in Parkinson's disease, which is in phase II clinical trails; and ACP-103 and ACP-104, for the treatment of schizophrenia. In addition, the company has neuropathic pain program in Phase I clinical trials and a glaucoma program in preclinical development in collaboration with Allergan, Inc. ACADIA Pharmaceuticals was founded by Mark R. Brann. The company was incorporated as Receptor Technologies, Inc. in 1993 and is headquartered in San Diego, California.
DENDREON CORPORATION (DNDN)
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of targeted therapies for cancer. Its portfolio of product candidates includes therapeutic vaccines, monoclonal antibodies, and small molecules to treat a range of cancers. The company's lead product candidate, Provenge (sipuleucel-T), is an investigational active cellular immunotherapy in Phase III clinical trials for the treatment of metastatic, androgen independent prostate cancer. In addition, Dendreon completed Phase I clinical trials for Neuvenge (lapuleucel-T), an investigational active cellular immunotherapy for the treatment of breast, ovarian, and other solid tumors. Its preclinical programs include monoclonal antibodies, therapies targeting the trp-p8 pathway and serine protease product candidates for the treatment of cancer. The company has research and development alliances with Genentech, Inc.; Abgenix, Inc.; and Dyax Corp. Dendreon was formed in 1992 and is headquartered in Seattle, Washington.
CELGENE CORPORATION (CELG)
Celgene Corporation engages in the discovery, development, and commercialization of therapies designed to treat cancer and immunological diseases through regulation of cellular, genomic, and proteomic targets. Its lead product, THALOMID, is used for the treatment of acute cutaneous manifestations of moderate to severe erythema nodosum leprosum, and as maintenance therapy to prevent and suppress cutaneous manifestation recurrences. The company, through a supply and distribution agreement, with GlaxoSmithKline, distributes ALKERAN, a therapy for the palliative treatment of multiple myeloma and for palliation of carcinoma of the ovary. Its RITALIN family of drugs includes Focalin (d-MPH), which is used for the treatment of attention deficit disorder and attention deficit hyperactivity disorder in school-age children. The company has various products in the preclinical and clinical-stage, including immunomodulatory drugs and selective cytokine inhibitory drugs. Celgene also produces compounds such as Benzopyrans and Selective Estrogen Receptor Modulators, Kinases Inhibitors, Tubulin Inhibitors, and Ligase Modulators. The company has collaborative agreements with Novartis Pharma AG; and strategic partnership agreements with Pharmion Corporation, Penn Pharmaceuticals Services Limited, and GlaxoSmithKline. The company markets and sells its products in the United States and Canada primarily through wholesale distributors. Celgene was organized in 1980 as a unit of Celanese Corporation and was spun-off in 1986. The company is headquartered in Warren, New Jersey.
TONGJITANG CHINESE MEDICINES COMPANY (TCM)
Tongjitang Chinese Medicines Company focuses on the development, manufacture, marketing, and sale of modernized traditional Chinese medicines. Its primary product, Xianling Gubao, is the traditional Chinese medicine for the treatment of osteoporosis. The company also manufactures and markets a portfolio of 10 other traditional Chinese medicines, including Zaoren Anshen Capsules, an OTC medicine for treating insomnia; and moisturizing and anti-itching capsules, an over-the-counter medicine for treating inflammatory skin conditions. Its product development pipeline includes potential uses of its existing products for additional medical indications and a number of new product candidates that are intended to address the medical needs in the therapeutic areas of women's health, mental health, and dermatology. The company sells its Xianling Gubao and other products exclusively through third-party distributors, who resell the products to hospitals and retail pharmacies in China. Tongjitang Chinese Medicines Company was founded in 1995 and is headquartered in Shenzhen, China.
Heska Corporation engages in the discovery, development, manufacture, marketing, sale, and distribution of veterinary products. The company operates in two segments, Core Companion Animal Health (CCA); and Other Vaccines, Pharmaceuticals, and Products (OVP). The CCA segment offers diagnostic and monitoring instruments and supplies; single use diagnostic and other tests; vaccines; and pharmaceuticals, primarily for canine and feline use. This segment primarily provides various products, including handheld electrolyte instrument, chemistry instrument, and hematology instrument and their consumables. The OVP segment offers private label vaccine and pharmaceuticals, primarily for cattle, as well as for other animals, including small mammals, horses, and fish. The company sells its products directly, as well as through independent third party distributors and other distribution relationships. The company was incorporated as Paravax, Inc. in 1988 and changed its name to Heska Corporation in 1995. Heska is headquartered in Loveland, Colorado.
EXACT SCIENCES CORPORATION (EXAS)
EXACT Sciences Corporation utilizes applied genomics to develop screening technologies for use in the detection of cancer. Certain of its technologies are offered in a commercial testing service, PreGen-Plus, developed by Laboratory Corporation of America Holdings. PreGen-Plus is a non-invasive stool-based DNA testing service for the detection of colorectal cancer in the average-risk population. EXACT Sciences was founded in 1995 and is headquartered in Marlborough, Massachusetts.
AMICUS THERAPEUTICS INC (FOLD)
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. The pharmacological chaperone technology involves the use of small molecules to restore biological activity in cells by binding to a misfolded protein caused by a genetic mutation. The company is targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Its lead compound includes Amigal, which is in Phase II clinical trials is used for the treatment of Fabry disease that causes kidney failure, cardiac abnormalities, and neurological complications. The company is also developing AT2101 for the treatment of Gaucher disease, which causes an enlarged liver and spleen, low levels of red blood cells and platelets, bone pain, and fractures; and AT2220 for the treatment of Pompe disease, which causes muscle weakness primarily affecting breathing, mobility, and heart function. The company has a strategic collaboration with Shire Human Genetic Therapies, Inc. to jointly develop pharmacological chaperone compounds for lysosomal storage disorders. Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury, New Jersey.
Eurand N.V., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Its lead product candidate includes EUR-1008, a porcine-derived proprietary enzyme replacement product for the treatment of exocrine pancreatic insufficiency. The company's product pipeline also comprises EUR-1047, an over-the-counter allergy medication; EUR-1002, which is a formulation of cyclobenzaprine for muscle relaxation; and EUR-1000 a formulation of propranolol for the treatment of hypertension and migraines. Its proprietary drug formulation technologies include customized release technologies to reduce daily dosing requirements and time the release of drugs in the body to increase efficacy or to reduce side effects; dosage form technologies to increase patient compliance through convenient dosage forms, such as orally disintegrating tablets and taste-masked drugs; bioavailability enhancement technology to improve drug absorption, resulting in dose reduction, and improved onset of action; and drug conjugation technology to extend drug half-life and to target specific organs or other biological targets, such as tumors. The company, formerly known as Eurand B.V., was incorporated in 1984 and is based in Amsterdam, the Netherlands.
Compugen, Ltd. develops platforms, discovery engines, and related technologies that enable the discovery and analysis of genes and gene-based products, as well as mRNAs and proteins. Its platforms comprise LEADS computational biology platform, which analyzes genomic and expressed sequence data to enable discovery of genes, mRNAs, and proteins; and discovery engines that enable its researchers to identify proteins and mRNAs with predetermined properties for therapeutic and diagnostic development. The company initiates the predictive modeling of alternative splicing, antisense, and the RNA editing that provides the basis for understandings of additional biological phenomena. Compugen has an early stage in-house pipeline consisting of selected therapeutic protein candidates discovered by the company; and additional discoveries that are out-licensed for development. It also focuses on novel splice variants of known and validated therapeutic proteins, as well as novel diagnostic markers. These novel proteins constitute an intellectual property portfolio, which includes novel prostate specific antigens, a novel vascular endothelial growth factor, a splice variant of CD40, and other proteins. The company operates primarily in the United States, Israel, Europe, and the Far East. Compugen has a collaboration agreement with Ortho-Clinical Diagnostics, Inc. for the development and commercialization of immunoassay diagnostic markers. The company was established in 1993 and is headquartered in Tel Aviv, Israel.
JAZZ PHARMACEUTICALS INC (JAZZ)
Jazz Pharmaceuticals, Inc. focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning. Its late-stage product candidates comprise Luvox CR, an extended release formulation of fluvoxamine, a selective serotonin reuptake inhibitor, which is used for the treatment of obsessive compulsive disorder and social anxiety disorder; and JZP-6, a liquid dosage form of sodium oxybate in Xyrem, for the treatment of fibromyalgia syndrome. The company's products in the clinical pipeline include JZP-4, a controlled release formulation of an anticonvulsant for the treatment of epilepsy and bipolar disorder; and JZP-8, a formulation incorporating a benzodiazepine, for the treatment of acute repetitive seizure clusters in refractory epilepsy patients. Its pipeline also comprise JZP-7, a formulation incorporating a dopamine agonist for the treatment of restless legs syndrome; and JZP-2, a formulation of a benzodiazepine for the acute treatment of panic attacks associated with panic disorder. The company has a product development and license agreement with Antares Pharma, Inc. Jazz Pharmaceuticals was founded in 2003 and is headquartered in Palo Alto, California.
ANIKA THERAPEUTICS INC (ANIK)
Anika Therapeutics, Inc. engages in the development, manufacture, and commercialization of therapeutic products and devices that are designed to repair, protect and heal bone, cartilage, and soft tissue. Its products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. HA enhances joint function and coats, protects, cushions, and lubricates soft tissues. The company's products include ORTHOVISC and HYVISC, an HA product used in the treatment of joint diseases, such as osteoarthritis, and viscoelastic products used in eye surgery. The ophthalmic products include AMVISC and AMVISC Plus product line, CoEase, STAARVISC-II, and ShellGel. Its injectable ophthalmic viscoelastic products are molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation. The company operates in the United States and Canada, the United Kingdom, Italy, and other European countries, Turkey, and parts of the Middle East. Anika Therapeutics was founded in 1983 and is headquartered in Woburn, Massachusetts.
AMYLIN PHARMACEUTICALS INC (AMLN)
Amylin Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and cardiovascular disease. Its primary drug candidates include exenatide and SYMLIN, which have completed phase III clinical trials for the treatment of diabetes. The company is developing exenatide for the treatment of type II diabetes, as well as studying a sustained release formulation of exenatide. Amylin Pharmaceuticals is developing SYMLIN for the treatment of patients with type I diabetes and insulin-using patients with type II diabetes. SYMLIN injection received the United States Food and Drug Administration approval for use in conjunction with insulin to treat diabetes. The company also has two early stage development programs for the treatment of obesity, including a phase II program for AC137 and AC162352 that completed a Phase I study. In addition, it is studying AC2592, which is in a phase II program for the treatment of patients with severe congestive heart failure, as well as AC3056, which is in phase I program for the treatment of atherosclerosis-related cardiovascular disease. Amylin Pharmaceuticals has a collaboration agreement with Eli Lilly and Company for the development and commercialization of exenatide, including sustained release formulations of that compound. It also has a collaboration agreement with Alkermes, Inc. for the development, manufacture, and commercialization of an injectable sustained-release formulation of exenatide. The company was co-founded by Howard E. Greene, Jr in 1987. Amylin Pharmaceuticals is headquartered in San Diego, California.
Dyax Corp. engages in the discovery, development, and commercialization of antibodies, small proteins, and peptides as therapeutic products, particularly in the areas of inflammation and oncology. As of December 31, 2004, the company had two product candidates in, or entering into, Phase II clinical trials for three indications. DX-88 is being studied for the treatment of both hereditary angioedema and for the prevention of blood loss, and other systemic inflammatory responses in on-pump open-heart surgery and other surgical indications, and DX-890 is being studied for the treatment of cystic fibrosis. In collaboration with Genzyme Corporation, Dyax is conducting an open-label, repeat dose Phase II clinical trial of DX-88. It has completed a Phase I/II study of DX-88 in the United States in patients undergoing coronary artery bypass grafting surgery. The company in collaboration with Debiopharm S.A. for DX-890 has completed two Phase IIa clinical trials, one in adults and one in pediatric cystic fibrosis patients. It uses its proprietary, patented technology, known as phage display, to identify a range of compounds consisting of monoclonal antibodies, small proteins, and peptides with the potential for the treatment of various diseases. The company has 12 discovery programs underway: 7 in oncology, which are focused on the discovery and development of therapies that fight cancer; 4 focused on targets that are believed to be mediators of inflammation; and 1 program focused on an infectious disease target. The company has collaboration agreements with AstraZeneca AB; Dendreon Corporation; Baxter Healthcare S.A.; Biogen Idec, Inc.; Inhibitex, Inc.; Debiopharm S.A.; and Syntonix Pharmaceuticals, Inc. Dyax was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
VIROPHARMA INCORPORATED (VPHM)
ViroPharma Incorporated, a pharmaceutical company, engages in the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. It markets and sells Vancocin Pulvules HCl, the oral capsule formulation, in the United States and its territories. Oral Vancocin is a potent antibiotic to treat antibiotic-associated pseudomembranous and enterocolitis. The company focuses on product development activities on viral diseases, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. Its products under core development program include CMV with an initial focus on CMV infections in recipients of hematopoietic stem cell/bone marrow transplants, and HCV. Noncore development programs target picornaviruses with intranasal pleconaril. The company has strategic relationships with Glaxo SmithKline, Wyeth, Schering-Plough, and Sanofi-Aventis. ViroPharma was incorporated in 1994 and is based in Exton, Pennsylvania.
TRANSITION THERAPEUTICS INC (TTHI)
Transition Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutics for various disease indications. Its lead products include ELND-005/AZD-103 for the treatment of Alzheimer's disease, and regenerative therapies E1-I.N.T. and GLP1-I.N.T. for the treatment of diabetes. ELND-005/AZD-103 completed multiple Phase I clinical studies and E1-I.N.T. completed a Phase IIa clinical trial. GLP1-I.N.T. is under preparation for Phase II clinical development. The company is also developing MS-I.E.T. for the treatment of multiple sclerosis and HCV-I.E.T. for the treatment of hepatitis C. In addition, Transition Therapeutics has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. The company has a partnership with Elan Pharma International Limited for the development and commercialization of ELND-005/AZD-103 therapeutic agent. Transition Therapeutics was founded in 1987. It was formerly known as Transition Therapeutics and Diagnostics, Inc. and changed its name to Transition Therapeutics, Inc. in 2000. The company is based in Toronto, Canada.
ONCOLYTICS BIOTECH INC (ONCY)
No description available.
Novavax, Inc. engages in the research, development, and commercialization of products for women's health and infectious diseases. Its primary product candidate ESTRASORB, a topical emulsion for estrogen therapy, is used for the treatment of vasomotor symptoms associated with menopause. The company's other products comprise a line of prenatal multivitamin tablets, including Novanatal, NovaStart, and Nestabs for use before, during, and after pregnancy; Gynodiol, an oral estrogen replacement therapy; AVC Cream for the treatment of vaginal infection; and Analpram HC for relief of inflammation and pruritus associated with conditions, such as hemorrhoids and anal fissures. Novavax is also developing ANDROSORB, a topical lotion for testosterone replacement therapy in women; ANDRO-Ject, which delivers therapeutic levels of androgen using a subcutaneous testosterone delivery system; and delivery systems, and therapeutic and preventative vaccines for various markets. In addition, the company conducts research and development on preventative vaccines and proteins for infectious diseases and cancers; and tolerogens to prevent the initiation and progression of stroke, heart attack, and other inflammatory diseases. Novavax has collaborative agreements with the National Institutes of Health for the development of AIDS vaccine and an avian flu vaccine to prevent a pandemic outbreak; National Cancer Institute to develop anticancer vaccines for the treatment of melanoma; NIAID, Walter Reed Army Institute for Research, and GlaxoSmithKline Pharmaceuticals for the development of vaccines to prevent hepatitis caused by Hepatitis E virus; and with Wave Biotech LLC to develop pandemic influenza vaccine production technologies. The company sells its products to obstetricians, gynecologists, managed care organizations, wholesalers, and retail pharmacies through direct sales force and distributors in the United States. Novavax was formed in 1987 and is headquartered in Malvern, Pennsylvania.
Medivation, Inc., a biopharmaceutical company, engages in the acquisition, research, and development of various medical technologies. It develops small molecule drugs for the treatment of Alzheimer's disease, Huntington's disease, and Hormone-Refractory Prostate Cancer. The company develops Dimebon for the treatment of Alzheimer's disease, which is in controlled Phase 2 efficacy study; Dimebon for the treatment of Huntington's disease, which is in a Phase 1-2a study; and proprietary small molecule MDV3100 for Hormone-Refractory Prostate Cancer. The company was founded in 2003 and is based in San Francisco, California.
DISCOVERY LABORATORIES INC (DSCO)
Discovery Laboratories, Inc., a biopharmaceutical company, develops Surfactant Replacement Therapies for respiratory diseases. The company offers Surfaxin, a protein B-based agent, for the prevention of respiratory distress syndrome in premature infants. Discovery Laboratories provides Surfaxin, which is in Phase 2 clinical trials, for bronchopulmonary dysplasia in premature infants, neonatal respiratory disorders in premature infants, and prophylactic/early treatment of meconium aspiration syndrome in full-term infants. It also offers its products for the treatment of acute respiratory distress syndrome in adults in the intensive care unit, as well as a Phase 1b trial of its lung surfactant delivered as an inhaled aerosol for patients who suffer from asthma. In addition, the company evaluating the development of aerosolized formulations of its SRT to prevent or treat acute lung injury, COPD, rhinitis, sinusitis, sleep apnea, and otitis media. It has a strategic alliance with Quintiles Transnational Corp.; PharmaBio Development, Inc.; Chrysalis Technologies; and Laboratorios del Dr. Esteve S.A. The company is headquartered in Warrington, Pennsylvania.
ARIAD PHARMACEUTICALS INC (ARIA)
ARIAD Pharmaceuticals, Inc. engages in the discovery and development of medicines to treat cancer by regulating cell signaling with small molecules. Its lead cancer product candidate, AP23573, is an mTOR inhibitor to treat solid tumors and hematologic malignancies. AP23573 is in multiple Phase II and Ib clinical trials as a single agent in patients with hematologic malignancies and solid tumors. Two multicenter Phase Ib studies with AP23573 in combination with other anti-cancer therapies, which are underway in Europe, focus primarily on patients with breast, ovarian, non-small-cell lung, and prostate cancers, as well as certain sarcomas. ARIAD also has an exclusive license to technology and patents related to certain NF-kB treatment methods, as well as the discovery, development, and use of drugs to regulate NF-kB cell-signaling activity, which might be useful in treating certain diseases. In addition, the company has a partnership with Medinol, Ltd., a cardiovascular medical device company, to develop and commercialize stents and other medical devices to deliver AP23573 to prevent reblockage of injured vessels following stent-assisted angioplasty, a common nonsurgical procedure for dilating or opening narrowed arteries. ARIAD was founded in 1991 by Harvey J. Berger and is headquartered in Cambridge, Massachusetts.
Exelixis, Inc. engages in the discovery and development of pharmaceutical products for the treatment of cancer, metabolic disorders, cardiovascular disease, and other serious diseases. Its clinical development pipeline includes various compounds in cancer and renal disease: XL119 (becatecarin), which is in a Phase III clinical trial in patients with inoperable bile duct tumors and which was exclusively licensed to Helsinn Healthcare SA with rights to reacquire commercial rights for North America; XL647, XL999, XL880, and XL820 that are in Phase I clinical trials in cancer; and XL844 and XL184, anticancer compounds for which it filed investigational new drug applications. The company's preclinical pipeline comprises six programs. The preclinical oncology programs consist of development candidates that focus on inhibiting the RAF (XL281), Akt/S6k (XL418), and IGF1R (XL228) kinases that are implicated in various cancers. In preclinical metabolic disease programs, which consist of Liver X Receptor, Farnesoid X Receptor, and Mineralocortiocoid Receptor programs, the company is developing small molecules that modulate nuclear hormone receptors implicated in various metabolic and cardiovascular disorders. Exelixis has alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, and Genentech. The company was founded as Exelixis Pharmaceuticals, Inc. in 1994 and changed its name to Exelixis, Inc. in 2000. Exelixis is headquartered in South San Francisco, California.
ZymoGenetics, Inc. engages in the discovery, development, and commercialization of therapeutic protein-based products for the treatment of human diseases. Its products include Novolin and NovoRapid marketed worldwide for the treatment of diabetes; NovoSeven marketed worldwide for the treatment of hemophilia; Regranex for the treatment of wound healing; GlucaGen for use as an aid for gastrointestinal motility inhibition and for the treatment of severe hypoglycemia in diabetic patients treated with insulin; and Cleactor for the treatment of myocardial infarction or heart attacks. The company's product pipeline comprises rhThrombin, TACI-Ig, and IL-21. rhThrombin is a topical hemostatic agent intended for the control of bleeding during surgical procedures has completed Phase 2 clinical trial. TACI-Ig is a soluble receptor for the treatment of autoimmune diseases and is developed in collaboration with Serono S.A. IL-21 is a protein for the treatment of cancer. ZymoGenetics was co-founded by Earl W. Davie, Benjamin D. Hall, and Michael Smith in 1981. The company is headquartered in Seattle, Washington.
LA JOLLA PHARMACEUTICAL COMPANY (LJPC)
La Jolla Pharmaceutical Company, a biopharmaceutical company, engages in the research and development of pharmaceutical products in the United States. Its principal product in development is Riquent, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. Riquent is in Phase III clinical trial. The company also develops small molecules for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders. La Jolla Pharmaceutical Company was founded in 1989 and is based in San Diego, California.
CytRx Corporation, a biopharmaceutical company, engages in the development and commercialization of human therapeutics primarily in the area of small molecules and ribonucleic acid interference (RNAi). It owns 3 clinical-stage compounds based on its small molecule ‘molecular chaperone' co-induction technology, as well as a targeted library of 500 small molecule drug candidates that would be used to screen for new drug candidates. The company initiated a Phase II clinical trial with its lead small molecule product candidate, Arimoclomol for the treatment for amyotrophic lateral sclerosis (ALS). Arimoclomol received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration. CytRx has also licensed from the University of Massachusetts Medical School (UMMS) the exclusive worldwide commercial rights to a novel DNA-based HIV vaccine technology, which demonstrated positive interim Phase I clinical trial results indicating its ability to produce potent antibody responses with neutralizing activity against multiple HIV viral strains. The company has a strategic alliance with UMMS to develop compounds in the areas of ALS, obesity, type II diabetes, and cytomegalovirus using RNAi technology, as well as a research program with Massachusetts General Hospital, Harvard University's teaching hospital, to use RNAi technology to develop a drug for the treatment of ALS. CytRx was incorporated in 1985 and is headquartered in Los Angeles, California.
MOMENTA PHARMACEUTICALS INC (MNTA)
Momenta Pharmaceuticals, Inc. engages in structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes. The company's products include M-Enoxaparin, a technology-enabled generic version of Lovenox and a low molecular weight heparin(LMWH), which is used to prevent and treat deep vein thrombosis and treat acute coronary syndromes; M-Dalteparin, also a technology-enabled generic version of the LMWH Fragmin. It also offers Glycoproteins, M118, pulmonary delivery of proteins, and sugar therapeutic, which are in preclinical stages. The company has collaboration agreements with Sandoz and Siegfried, Inc. and Siegfried, Ltd. The company was founded by Ganesh Venkataraman in 2001 as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in 2002. Momenta is based in Cambridge, Massachusetts.
AMERICAN ORIENTAL BIOENGINEERING INC (AOB)
American Oriental Bioengineering, Inc., together with its subsidiaries, engages in the development, manufacture, and commercialization of plant-based pharmaceutical (PBP) and plant-based nutraceutical (PBN) products. It provides PBP products that include Shuanghuanlian Lyophilized injection powder, an anti-viral injection for treating respiratory diseases; Cease Enuresis Soft Gel and Patch, a prescription medicine formulated to help alleviate bed-wetting and incontinence, as well as offers over-the-counter drugs, such as Jinji capsules and pills to treat endometritis, annexitis, and pelvic inflammations; and Double Ginseng Yishen grains for people suffering from neurosis, vegetative nerve functional disturbance, and hypo-immunity. The company's PBN products include soy peptide products series, which offers soypeptide tablets, powder, and coffee; and compound bio-functional beverage that is derived from honey products, marine plants, and natural herbs. It sells its products directly to retail stores, pharmacies, hospitals, and to independent distributors. American Oriental Bioengineering is based in Shenzhen, China.
Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of drugs for the treatment of multiple diseases and disorders of the central nervous system. As of December 31, 2006, the company had four clinical-stage product candidates and three preclinical product candidates in its product portfolio. Its product candidates are in development as treatments for target indications in three therapeutic areas: cognitive impairment, depression and anxiety, and pain. The company principally offers Inversine, which is approved for marketing for the management of moderately severe to severe essential hypertension, a high blood pressure disorder. Its product candidates include TC-1734, a Phase II clinical trial completed product for the treatment of Alzheimer's disease, cognitive deficits in schizophrenia, and other conditions characterized by cognitive impairment, such as attention deficit hyperactivity disorder, age associated memory impairment, and mild cognitive impairment. Targacept's product candidates also include TC-2696 for acute post-operative pain; mecamylamine hydrochloride, the active ingredient in Inversine; and TC-5214, one of the enantiomers of mecamylamine hydrochloride; TC-2216, a phase I product for depression and anxiety disorders; and TC-5619 for various conditions, such as schizophrenia, cognitive impairment, and inflammation. The company has a collaborative research and license agreement with AstraZeneca AB for development and commercialization of TC-1734 to treat Alzheimer's disease, cognitive deficits in schizophrenia, and other cognitive disorders. Targacept was founded in 1997 and is based in Winston-Salem, North Carolina.
NABI BIOPHARMACEUTICALS (NABI)
Nabi Biopharmaceuticals engages in the development and commercialization of products in the areas of Gram-positive bacterial infections, hepatitis, nephrology, and nicotine addiction. The company markets three products: PhosLo for treatment of hyperphosphatemia in end-stage renal failure patients; Nabi-HB for the prevention of hepatitis B infections; and Aloprim for the treatment of chemotherapy-induced hyperuricemia or high uric acid levels. Nabi also has products in various stages of clinical and preclinical development. Its advanced StaphVAX, which is in Phase III clinical development, is designed to prevent the most dangerous and prevalent strains of Staphylococcus aureus bacterial infections. The company's other products in development include Altastaph, an antibody for prevention of Staphylococcus aureus infections; NicVAX, a vaccine to treat nicotine addiction; and Civacir, an antibody for preventing hepatitis C virus reinfection in liver transplant patients. The company also offers contract manufacturing services. Nabi sells its biopharmaceutical products to wholesalers, distributors, hospitals, and home healthcare companies, as well as sells its antibody products to pharmaceutical and diagnostic product manufacturers. The company has strategic alliances with Public Health Services/National Institutes of Health; Chiron Corporation; Pfizer; and Cambrex BioScience of Baltimore, Inc. Nabi is headquartered in Boca Raton, Florida.
NEUROCRINE BIOSCIENCES INC (NBIX)
Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Its product candidates address various pharmaceutical markets, including insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes, and other neurological and endocrine related diseases and disorders. Neurocrine has 17 programs in various stages of research and development. Its lead clinical development program, indiplon, for the treatment of insomnia, partnered with Pfizer, Inc., is in Phase III clinical development. The company completed three Phase I single and multiple dose trials with Gonadotropin-releasing Hormone, GnRH, for the treatment of women's health disorders. It also has two Altered Peptide Ligand products in Phase II clinical development, NBI-5788 for multiple sclerosis and NBI-6024 for Type I Diabetes. Neurocrine initiated a Phase I clinical trial with its proprietary compound, urocortin 2 for treating mild to moderate congestive heart disease. The company's CRF program, partnered with GlaxoSmithKline, is developing multiple compounds that are in various stages of research and preclinical development. It also has strategic alliances with Almirall Prodesfarma, S.A.; Wyeth Holdings Corporation; and Eli Lilly and Company. The company was incorporated in 1992 and is headquartered in San Diego, California.
VICAL INCORPORATED (VICL)
Vical Incorporated engages in the research and development of biopharmaceutical products for the prevention and treatment of serious or life-threatening diseases. The company focuses on the development of biopharmaceutical product candidates based on its patented deoxyribonucleic acid (DNA) delivery technologies. It develops various DNA-based vaccines and therapeutics for the prevention or treatment of infectious diseases, cancer, and cardiovascular diseases. Vical primarily develops its cancer immunotherapeutics, Allovectin-7 and IL-2/Electroporation, as well as a plasmid DNA vaccine for cytomegalovirus. Allovectin-7, which completed its Phase II clinical trials, is a plasmid/lipid complex containing the DNA sequences encoding HLA-B7 and ß2 microglobulin, which together form a Class I Major Histocompatibility Complex antigen. Allovectin-7 is being developed as a treatment for metastatic melanoma, a form of skin cancer. IL-2/Electroporation program that is in Phase 1 clinical testing is a gene-based, electroporation enhanced delivery of interleukin-2, or IL-2, a potent immunotherapeutic agent, as a treatment for solid tumors, with an initial indication in metastatic melanoma. Vical also develops an anthrax vaccine, which is in Phase 1 clinical testing. The company was incorporated in 1987 and is based in San Diego, California.
3SBio, Inc., a biotechnology company, focuses on the research, development, manufacture, and marketing of biopharmaceutical products primarily in the People's Republic of China. Its product candidates are designed to address unmet medical needs in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. The company's principal product, EPIAO is an injectable recombinant human erythropoietin that is used to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions. It also offers TPIAO, a recombinant human thrombopoietin indicated for the treatment of chemotherapy-induced thrombocytopenia, a deficiency of platelets. In addition, the company markets two protein-based therapeutics, Intefen, a recombinant interferon alpha-2a product indicated for the treatment of carcinoma of the lymphatic or hematopoietic system and viral infectious diseases; and Inleusin, a recombinant human interleukin-2 product indicated for the treatment of renal cell carcinoma, metastatic melanoma, thoratic fluid build-up caused by cancer, and tuberculosis. Further, the company's product pipeline includes various protein-based therapeutics, including NuPIAO, a second-generation EPIAO product candidate; TPIAO for the treatment of idiopathic thrombocytopenic purpura; NuLeusin, a next-generation Inleusin product candidate; a human papilloma virus vaccine for the prevention of cervical cancer; and an anti-TNF humanized monoclonal antibody product candidate for the treatment of rheumatoid arthritis and other autoimmune diseases. 3SBio sells its products through a network of distributors to healthcare providers, including hospitals, clinics, and dialysis centers. It also markets its products through distribution agreements with local agents in various developing countries. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
Trimeris, Inc. engages in the identification, development, and commercialization of therapeutic agents that block viral infection by inhibiting viral fusion with host cells. Its principal drug candidate, Fuzeon, is a human immunodeficiency virus (HIV) fusion inhibitor approved in the United States, Canada, European Union, and other countries for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The company has a collaboration agreement with F. Hoffmann-La Roche, Ltd. to develop and market Fuzeon and T-1249, a replacement compound. Trimeris was founded by Dani Bolognesi and Tom Matthews in 1993 and is based in Morrisville, North Carolina.
CYPRESS BIOSCIENCE INC (CYPB)
Cypress Bioscience, Inc., a biotechnology company, develops products for the treatment of Functional Somatic Syndromes, such as Fibromyalgia Syndrome (FMS), as well as other related chronic pain and central nervous system disorders. It develops Milnacipran, a norepinephrine serotonin reuptake inhibitors agent for the treatment of FMS. As of March 31, 2005, Milnacipran was in a Phase III trial for the treatment of FMS. Milnacipran is a compound, which exerts its effect by inhibiting the reuptake of both norepinephrine and serotonin, two neurotransmitters in regulating pain and mood. The company has a collaboration agreement with Forest Laboratories, Inc.; and a reformulation and new product agreement with Collegium Pharmaceutical, Inc. Cypress Bioscience is based in San Diego, California.
CAMBREX CORPORATION (CBM)
Cambrex Corporation and its subsidiaries provide products and services to accelerate drug discovery, development, and manufacturing processes for human therapeutics worldwide. It operates through three segments: Bioproducts, Biopharma, and Human Health. The Bioproducts segment offers research products and therapeutic application products; The Biopharma segment provides contract biopharmaceutical process development and manufacturing services; and The Human Health segment produces active pharmaceutical ingredients and pharmaceutical intermediates for use in the production of prescription and over-the-counter drug products, as well as other custom chemicals derived from organic chemistry. Cambrex Corporation sells its products through its direct sales force, independent distributors, and its e-commerce Web site to pharmaceutical and biopharmaceutical companies, generic drug companies, biotechnology companies, and research organizations. The company was founded in 1981 and is based in East Rutherford, New Jersey.
REPROS THERAPEUTICS INC (RPRX)
Repros Therapeutics, Inc., a development stage biopharmaceutical company, focuses on the development of drugs to treat hormonal and reproductive system disorders. The company's lead compound includes Proellex, a Phase II clinical trial product, for the treatment of uterine fibroids and endometriosis; and Androxal, a Phase III clinical trial product, which causes increased testosterone secretion from the testes, for the treatment of testosterone deficiency in men resulting from secondary hypogonadism. It also offers phentolamine-based products, such as VASOMAX for the treatment of male erectile dysfunction under the brand name, Z-Max, as well as Bimexes, an oral therapy for men with mild to moderate impotence, and ERxin, an injectable therapy for the treatment of severe erectile dysfunction. The company, formerly known as Zonagen, Inc., was founded in 1987 and changed its name to Repros Therapeutics, Inc. in 2006. Repros Therapeutics is based in The Woodlands, Texas.
ImmunoGen, Inc. engages in the discovery and development of therapeutic monoclonal antibodies and treatments in the field of oncology in the United States and the United Kingdom. It develops novel, targeted therapeutics using its tumor-activated prodrug (TAP) technology, which uses monoclonal antibodies to deliver potent cell-killing agents. The company's two leading product candidates include huN901-DM1 and huC242-DM4, which are in clinical testing stage. Its huN901-DM1 product candidate consists of the huN901 antibody, which binds to the CD56 antigen, a cytotoxic agent. The company's second clinical TAP product candidate, huC242-DM4, consists of the humanized C242 monoclonal antibody with its cytotoxic agent attached and is in development for the treatment of colorectal, pancreatic, and other cancers. ImmunoGen also licenses its TAP technology to other biotechnology and pharmaceutical companies. ImmunoGen has collaborative partnerships with sanofi-aventis, Biogen Idec, Inc.; Boehringer Ingelheim International GmbH; Centocor, Inc.; Millennium Pharmaceuticals, Inc.; Abgenix, Inc.; Genentech, Inc.; and GlaxoSmithKline plc. The company was organized in 1981 and is headquartered in Cambridge, Massachusetts.
BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI)
BioDelivery Sciences International, Inc. operates as a specialty biopharmaceutical company that uses its licensed and patented drug delivery technologies to develop and commercialize new formulations of proven therapeutics targeted at acute treatment opportunities, such as pain, anxiety, nausea and vomiting, and infections. Its lead product under development is Emezine, which is used for treating nausea and vomiting, is in pre-registration stage. The company's licensed drug delivery technologies include the Bioral nanocochleate drug delivery technology, which is designed for a range of applications; and the BEMA drug delivery disc technology, which is applied to the inner cheek membrane. Its Bioral Amphotericin B is an anti-fungal treatment for treating systemic fungal infections. The company's lead BEMA product under development is BEMA Fentanyl, a treatment for cancer pain. BioDelivery Sciences is also developing BEMAT Long Acting Analgesic for treating pain conditions, including post operative and chronic pain due to osteoarthritis, lower back disorders, and rheumatoid arthritis. In addition, the company has a clinical development and license agreement with Clinical Development Capital, LLC relating to its BEMA Fentanyl product. BioDelivery Sciences was incorporated in 1997 and is headquartered in Morrisville, North Carolina.
BIOCRYST PHARMACEUTICALS INC (BCRX)
BioCryst Pharmaceuticals, Inc. engages in the design, optimization, and development of small-molecule drugs that treat cancer, cardiovascular, and autoimmune diseases, as well as viral infections. The company focuses on building potent, selective inhibitors of enzymes associated with targeted diseases. BioCryst Pharmaceuticals integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to use structure-based drug design to discover and develop small molecule pharmaceuticals. Its lead product candidate, Fodosine, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is in a Phase IIa trial for patients with T-cell leukemia and in a Phase I trial with an oral formulation in cutaneous T-cell lymphoma. The company's pipeline products include PNP Inhibitor (BCX-4208), Hepatitis C Polymerase Inhibitors, and Tissue Factor/Factor VIIa Inhibitors. PNP Inhibitor (BCX-4208), a phase I clinical trial product, is intended for the treatment of T-cell mediated autoimmune diseases, including psoriasis. Hepatitis C Polymerase Inhibitor, a product under lead optimization stage, is intended for the treatment of viral infections. Tissue Factor/Factor VIIa, a product under lead optimization stage, is intended for the treatment of acute coronary syndromes and complications associated with cardiovascular procedures. The company has strategic agreement with Sunol Molecular Corp. to conduct research and supply of protein targets for drug design for its cardiovascular program. BioCryst Pharmaceuticals was co-founded in 1986 by Charles E. Bugg, John A. Montgomery, and William M. Spencer, III. The company is headquartered in Birmingham, Alabama.
PDL BioPharma, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for treatment of inflammation and autoimmune diseases, acute cardiac conditions, and cancer. It markets and distributes various biopharmaceutical products, including Cardene I.V. for the short-term treatment of hypertension; Retavase, a fibrinolytic agent for the management of acute myocardial infarction or heart attack in adults for the improvement of ventricular function; and IV Busulfex that is used as a conditioning agent in blood or marrow transplantation in chronic myelogenous leukemia. The company also develops various other products, such as Daclizumab for the treatment of asthma and multiple Sclerosis; Ularitide to treat decompensated congestive heart failure; Terlipressin for the treatment of Type 1 hepatorenal syndrome; HuZAF to treat crohn's disease; Nuvion for the treatment of severe steroid-refractory ulcerative colitis; and M200 to treat solid tumors. PDL BioPharma markets its biopharmaceutical products in the United States and Canada through its hospital sales force. The company was founded by Laurence Jay Korn in 1986. It was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in June 2005. PDL BioPharma is headquartered in Fremont, California.
ACHILLION PHARMACEUTICALS INC (ACHN)
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. It focuses on the development of antivirals for the treatment of HIV infection and chronic hepatitis C; and antibacterials for the treatment of serious hospital-based bacterial infections. The company's lead drug candidate is elvucitabine, an antiviral in phase II clinical trials for the treatment of HIV infection. It also develops ACH-702, a preclinical candidate for the treatment of serious hospital-based bacterial infection; and NS4A Antagonists, a preclinical-stage program for chronic hepatitis C. The company has research collaboration with Gilead Sciences, Inc. to develop and commercialize compounds for the treatment of chronic hepatitis C. Achillion was founded in 1998 and is based in New Haven, Connecticut.
Amgen, Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products in the areas of nephrology, supportive cancer care, and inflammatory disease. Its products primarily include EPOGEN, Aranesp, Neulasta, NEUPOGEN, and ENBREL, which is marketed under a co-promotion agreement with Wyeth in the United States and Canada. EPOGEN and Aranesp stimulate the production of red blood cells to treat anemia. Neulasta and NEUPOGEN selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections. ENBREL blocks the biologic activity of tumor necrosis factor (TNF) by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. It sells its products to healthcare providers, including clinics, hospitals, and pharmacies primarily in the United States, Europe, Canada, and Australia. Amgen has collaboration and license agreement with Memory Pharmaceuticals Corp. to produce drugs for neurological and psychiatric disorders; and a drug-discovery agreement with Galapagos Genomics NV. The company was established by Bill Bowes, Franklin Johnson, Sam Wohlsteadter, and Raymond Baddour in 1980. Amgen is headquartered in Thousand Oaks, California.
Micromet, Inc., a biopharmaceutical company, develops antibody-based products for cancer, inflammatory, and autoimmune diseases. Its products under clinical trials include MT103, a Phase I clinical trial product candidate for the treatment of patients with non-Hodgkins lymphoma; and Adecatumumab, a recombinant human monoclonal antibody that is under clinical Phase IIa status for metastatic breast cancer and other adenocarcinoma indications, and is being evaluated in clinical Phase Ib trials for treatment of metastatic breast cancer in combination with docetaxel. The company's preclinical development products include MT203 and MT204 human antibodies to treat various acute and chronic inflammatory diseases, including rheumatoid arthritis, asthma, psoriasis, and multiple sclerosis; EphA2, a cell surface membrane-associated receptor tyrosine kinase for the treatment of cancer; CEA, which is indicated for the treatment of tumors of epithelial origin, such as colorectal carcinoma, lung adenocarcinoma, mucinous ovarian carcinoma, and endometrial adenocarcinoma; MORAb28, a human IgM monoclonal antibody binding to an antigen that is identified as a cell-surface antigen present on human melanomas and tumors of neuroectodermal origin; and MT110, a molecule that combines binding specificities for EpCAM and for CD3 on T cells. Micromet's product pipeline also consists of D93, a humanized, anti-metastatic, and anti-angiogenic monoclonal antibody for treatment of patients with solid tumors. It has strategic collaborations with MedImmune, Inc. for MT103; Nycomed for development of anti-GM-CSF antibodies; and Merck Serono Biopharmaceuticals S.A. for adecatumumab. The company is headquartered in Bethesda, Maryland.
OPTIMER PHARMACEUTICALS INC (OPTR)
Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products primarily to treat gastrointestinal infections and related diseases. Its product candidates include Difimicin (OPT-80), which is in Phase 3 registration trial for the treatment of Clostridium Difficile-associated diarrhea (CDAD), and for the prevention of CDAD; and prevention of nosocomial vancomycin-resistant enterococci bloodstream infections, and methicillin-resistant staphylococci prophylaxis. The company is also developing Prulifloxacin, which is under Phase 3 trial for the treatment of infectious diarrhea, including traveler's diarrhea; OPT-88, a therapy for osteoarthritis; OPT-822/OPT-821, a cancer immunotherapy for the treatment of metastatic breast cancer; and OPT-1068 and OPT-1273 antibiotics for the treatment of upper and lower respiratory tract infections. It has a collaboration agreement with Par Pharmaceutical, Inc. for the clinical development and commercialization of Difimicin; as well as a collaborative research and development, and license agreement with Cempra Pharmaceuticals, Inc. to discover, develop, and commercialize drugs based on macrolide and ketolide compounds. Optimer Pharmaceuticals was founded in 1998 and is headquartered in San Diego, California.
CYCLACEL PHARMACEUTICALS INC (CYCC)
Cyclacel Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of mechanism-targeted drugs to treat human cancers and various serious disorders. The company is evaluating seliciclib (CYC202), an orally available cyclin dependent kinase inhibitor, which is in Phase II clinical trials for the treatment of lung cancer. Its product candidates also comprise sapacitabine, an orally available nucleoside analog, which is in phase I clinical trial; and CYC116, an orally-active Aurora kinases inhibitor for the treatment of cancer. In addition, the company has preclinical stage programs for the treatment of cancer, inflammatory kidney disease, HIV/AIDS, and type 2 diabetes. Cyclacel Pharmaceuticals is headquartered in Berkeley Heights, New Jersey.
IDENIX PHARMACEUTICALS INC (IDIX)
Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of human viral and other infectious diseases. It primarily focuses on the treatment of infections caused by hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The company's HBV product candidates include telbivudine for the treatment of an inflammatory liver disease associated with chronic HBV infection; and valtorcitabine, which is in phase IIb clinical trial. Idenix also develops valopicitabine or NM283 for the treatment of HCV, as well as a product candidate from the class of compounds known as nonnucleoside reverse transcriptase inhibitors for the treatment of HIV. Its Telbivudine product candidate is in phase III clinical trial, and valopicitabine or NM283 product candidate is in phase IIb clinical trial. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Idenix Pharmaceuticals, Inc. is a subsidiary of Novartis Pharma AG.
MOLECULAR INSIGHT PHARMACEUTICALS INC (MIPI)
Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and cardiology in the United States. The company's products under development include Azedra, a Phase I clinical-stage radiotherapeutic product candidate for the treatment of adult patients with various forms of neuroendocrine cancer, such as carcinoid or pheochromocytoma; and Onalta, a clinical-stage radiotherapeutic product candidate for the treatment of somatostatin positive pancreatic neuroendocrine and carcinoid tumors. It is also developing Zemiva, a molecular imaging pharmaceutical product candidate for the diagnosis of cardiac ischemia or insufficient blood flow to the heart in the emergency department setting, as well as for the diagnosis of coronary disease in the non-acute setting. In addition, its products under development include Solazed, a radiotherapeutic for the treatment of malignant metastatic melanoma; MIP-220, a molecular imaging pharmaceutical product for detection of prostate-specific membrane antigen, which enables the detection and monitoring of prostate cancer; MIP-190 to assess the progression of heart failure through the monitoring of angiotensin converting enzyme in human hearts; and MIP-170D, a molecular imaging pharmaceutical compound to aid in the objective diagnosis of Parkinson's disease and attention deficit hyperactivity disorder. The company was founded in 1997 as Imaging Biopharmaceuticals, Inc. and changed its name to Biostream, Inc. in 1998. Further, it changed its name to Molecular Insight Pharmaceuticals, Inc. in 2003. The company is based in Cambridge, Massachusetts.
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics primarily related to the treatment of serious men's health conditions and oncology. The company's drug discovery and development programs focus on small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones. It markets FARESTON, a toremifene citrate tablets, for the treatment of metastatic breast cancer. GTx develops ACAPODENE for two separate indications in men, a Phase III clinical trial product, for the prevention of prostate cancer in high risk men, and a Phase III clinical trial product for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer. The company also develops andarine, a selective androgen receptor modulator (SARM); as well as a second SARM, ostarine, for andropause and other chronic conditions related to aging, including sarcopenia. Further, its preclinical pipeline includes the specific product candidates prostarine, a SARM for benign prostatic hyperplasia, and andromustine, an anticancer drug, for hormone refractory prostate cancer. Additionally, it develops andarine for the treatment of cachexia from various types of cancer. The company has joint collaboration and license agreement with Ortho Biotech Products L.P. for the clinical development of andarine and specified backup SARM compounds. It also has collaboration agreements with Hybritech, Inc., diaDexus, Inc., and Tessera, Inc. GTx was co-founded by Mitchell S. Steiner and Marc S. Hanover in 1997. The company is based in Memphis, Tennessee.
Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. Its lead product candidate includes Hematide, a synthetic peptide-based erythropoiesis stimulating agent, which is designed to treat anemia associated with chronic kidney disease and cancer. The company is conducting phase II clinical trials of Hematide in dialysis patients, predialysis patients, cancer patients on chemotherapy and patients with PRCA. It is also developing a pipeline of peptide based drug candidates, including Adeptide, a peptide based, non-injectable erythropoiesis stimulating agent; the Innotide program that comprises a family of peptide based drug candidates for use in the area of tissue protection in preclinical models of stroke, myocardial infarct, and renal injury; and Angiotide, a synthetic peptide for treating cancer by blocking angiogenesis, or blood vessel formation in tumors. Affymax has strategic alliances with Takeda Pharmaceutical Company Limited to develop and commercialize Hematide; EntreMed, Inc. for preclinical research of Angiotide; and Nektar Therapeutics AL, Corporation. The company was founded in 2001 and is based in Palo Alto, California.
MEDICIS PHARMACEUTICAL CORPORATION (MRX)
Medicis Pharmaceutical Corporation, a specialty pharmaceutical company, focuses on the development and marketing of products for the treatment of dermatological, aesthetic, and podiatric conditions in the United States and Canada. It offers a range of products addressing various conditions, including acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, eczema, skin and skin-structure infections, seborrheic dermatitis, and cosmesis. The company's product portfolio comprises DYNACIN, an oral adjunctive treatment for moderate to severe acne; LOPROX, a topical treatment for certain fungal and yeast infections; OMNICEF, a patented oral cephalosporin for skin and skin-structure infections; PLEXION, topical treatments for rosacea and acne-related conditions; RESTYLANE, an injectable gel for treatment of fine lines and wrinkles, shaping facial contours, and correcting deep facial folds; TRIAZ, topical patented gel, cleanser, and patent-pending pad treatments for acne; and VANOS, topical corticosteroid for the treatment of plaque type psoriasis in adult patients. It also offers PERLANETM and RESTYLANE FINE LINES, which are injectable, transparent, and nonanimal-stabilized-hyaluronic acid gels for the treatment of fine lines and wrinkles, and correcting deep facial folds. The company's nondermatological product line includes AMMONUL, as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle; and BUPHENYL, an adjunctive maintenance therapy for urea cycle disorders. Its customers include wholesale pharmaceutical distributors and other drug chains. The company has a strategic alliance with aaiPharma, Inc. Medicis Pharmaceutical was founded in 1987 and is headquartered in Scottsdale, Arizona.
EntreMed, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics primarily for the treatment of cancer. It develops multimechanism oncology and anti-inflammatory drugs that target disease cells directly and the blood vessels that nourish them. The company's lead drug candidate Panzem (2-methoxyestradiol or 2ME2) is in clinical trials for cancer, as well as in preclinical development for nononcology indications. Panzem is in Phase I and Phase II clinical trials. The company also develops various molecules, including analogs of 2ME2, modulators of fibroblast growth factor-2 activity, tissue factor pathway inhibitor peptides, and proteinase activated receptor-2 antagonists to inhibit tumor growth and angiogenesis activities. The company has a strategic alliance with Allergan to develop and commercialize small molecule angiogenic inhibitors for the treatment and prevention of diseases and conditions of the eye; research collaboration with Affymax, Inc. to identify lead tissue factor pathway inhibitor drug candidates for the treatment of cancer; and a cooperative research and development agreement with the National Cancer Institute to evaluate the role of HIF-1alpha inhibition in the treatment of cancer. EntreMed was incorporated in 1991 and is based in Rockville, Maryland.
HALOZYME THERAPEUTICS INC (HALO)
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of products based on the extracellular matrix for the drug delivery, oncology, and dermatology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. Its Enhanze Technology is a novel drug delivery platform, which is designed to increase the absorption and dispersion of biologics. The company has partnership with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets. In addition, Halozyme holds Food and Drug Administration approval for two products: Cumulase and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. The company has partnership with Baxter Healthcare Corporation for HYLENEX. Halozyme also develops various enzymes. The company was founded in 1998 and is based in San Diego, California.
PROGENICS PHARMACEUTICALS INC (PGNX)
Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. It offers products for the areas of symptom management and supportive care, and the treatment of HIV infection and cancer. The company's methylnaltrexone is designed to reverse the side effects of opioid pain medications while maintaining pain relief and also for the management of post-operative bowel dysfunction caused by endogenous, or naturally occurring, opioids. The company is developing viral-entry inhibitors in the area of HIV infection, including PRO 140, a humanized monoclonal antibody targeting the HIV coreceptor CCR5; PRO 542, a genetically engineered molecule designed to neutralize HIV by preventing it from attaching to the CD4 receptor on the surface of immune system cells; ProVax for the prevention of HIV infection or as a therapeutic treatment for HIV-positive individuals. The company, in collaboration with Cytogen Corporation, is developing immunotherapies for prostate cancer, including a human monoclonal antibody directed against prostate-specific membrane antigen, a protein found on the surface of prostate cancer cells. It is also developing vaccines designed to stimulate an immune response to PSMA. The company is also developing a cancer vaccine, GMK, which is in phase 3 clinical trials for the treatment of malignant melanoma. Progenics Pharmaceuticals has agreement with Wyeth Pharmaceuticals for the joint development and commercialization of methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction. The company was founded by Paul J. Maddon. Progenics Pharmaceuticals was incorporated in 1986 and is based in Tarrytown, New York.
InterMune, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies in pulmonology and hepatology. The company markets various products, including Actimmune (interferon gamma-1b) for the treatment of severe osteopetrosis, and chronic granulomatous disease; Infergen (consensus interferon alfacon-1) for the treatment of patients with compensated liver disease with chronic hepatitis C virus infections; and Amphotec (amphotericin B cholesteryl sulfate complex for injection) for the treatment of invasive aspergillosis. In pulmonology area, InterMune develops Actimmune, a second phase III clinical trial, which is used for the treatment of patients with idiopathic pulmonary fibrosis; and interferon gamma-1b under the name Imukin. In hepatology area, it is developing once-daily Infergen in combination with ribavirin therapy for the treatment of patients suffering from chronic HCV infections; Infergen in combination with Actimmune, which is in Phase IIb clinical trial for the treatment of hepatitis C nonresponders; and PEG-Alfacon-1 that completed phase I clinical trial for the treatment of chronic HCV infections. In addition, the company evaluates Actimmune in patients with ovarian cancer in a Phase III trial. InterMune has collaboration and licensing agreements with Boehringer Ingelheim International GmbH; Maxygen Holdings, Ltd.; and Array BioPharma, Inc. The company was incorporated in 1998 and is headquartered in Brisbane, California.
OSIRIS THERAPEUTICS INC (OSIR)
Osiris Therapeutics, Inc., a biotechnology company, commercializes stem cell products from adult bone marrow in the United States. It develops and markets products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. The company's products include Osteocel for use in spinal fusion and other orthopedic surgical procedure; and Prochymal, a phase II and III clinical trial product for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, and Crohn's Disease. It also offers Chondrogen, which is in phase I/II clinical trial used for the treatment of meniscus regeneration and cartilage protection; and Provacel, a phase I clinical trial product for repairing heart tissue following a heart attack. Osiris Therapeutics has strategic alliance with JCR Pharmaceuticals Co., Ltd.; and collaboration agreement with Boston Scientific Corporation to develop applications of MSC technology to treat acute myocardial infarction and chronic ischemia. The company was founded in 1992 and is headquartered in Baltimore, Maryland.
COMBINATORX INCORPORATED (CRXX)
CombinatoRx, Incorporated, a biopharmaceutical company, focused on developing synergistic combinations of approved drugs, with a portfolio of product candidates in clinical development. It offers CRx-102, CRx-139, and CRx-170, the oral synergistic combination drug candidates; CRx-150, an orally administered synergistic cytokine modulator; CRx-191 and CRx-197 for the topical treatment of inflammatory dermatoses; CRx-026, a dual-action anti-tumor drug candidate; and CRx-401, an anti-diabetic agent. CombinatoRx has research and development collaboration agreements with Spinal Muscular Atrophy Foundation; Accelerate Brain Cancer Cure, Inc.; Science Applications International Corporation; Angiotech Pharmaceuticals, Inc.; CHDI, Inc.; National Institutes of Health; Cystic Fibrosis Foundation Therapeutics Incorporated; HenKan Pharmaceutical Company; Gene Network Sciences, Inc.; and Fovea Pharmaceuticals SA. The company was founded in 2000 and is based in Boston, Massachusetts.
Crucell N.V. engages in the discovery, development, and production of various biopharmaceutical products for the prevention and treatment of infectious diseases using its proprietary technologies. It develops vaccines and antibodies against influenza, West Nile virus, Ebola, malaria, tuberculosis, and rabies using PER.C6, AdVac, and MAbstract technologies. The company's PER.C6 technology encompasses a human cell line production system to develop biopharmaceutical products. Its AdVac technology is a recombinant vector technology that develops novel adenoviral-based products. Crucell's MAbstract phage antibody display technology is used to discover disease associated molecules and develop human antibodies. The company licenses its technologies to pharmaceutical and biotechnology companies. Crucell has a research and licensing agreement with ACE BioSciences A/S to discover antibody therapies to combat serious iatrogenic infections, including those caused by antibiotic-resistant bacteria; and a research and development agreement with the Walter Reed Army Institute of Research to evaluate Crucell's PER.C6 technology for the development of vaccines against the flaviviruses dengue fever and Japanese encephalitis. The company is headquartered in Leiden, the Netherlands.
Theravance, Inc. engages in the discovery, development, and commercialization of small molecule medicines for respiratory disease, bacterial infections, overactive bladder, and gastrointestinal disorders. As of April 7, 2005, telavancin, the company's injectable antibiotic, was in Phase 3 clinical studies for the treatment of Gram-positive infections and in patients whose infections were due to methicillin-resistant Staphylococcus aureus in both complicated skin and skin structure infections and hospital-acquired pneumonia. Its other product candidates in development include TD-6301 for overactive bladder; TD-2749 and TD-5108 for gastrointestinal motility dysfunction; and TD-4756 for emergence from hypnosis. Theravance has various other product candidates in the identification and preclinical testing stages. The company has a collaboration agreement with GlaxoSmithKline (GSK) to develop and commercialize long acting beta2 agonist product candidates for the treatment of asthma and chronic obstructive pulmonary disease. It also has a strategic alliance with GSK. Theravance, Inc. has collaboration with Astellas Pharma, Inc. for the development and commercialization of its investigational antibiotic, telavancin. The company was co-founded by P. Roy Vagelos and George M. Whitesides in 1996. It was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in 2002. Theravance is headquartered in South San Francisco, California.
TRUBION PHARMACEUTICALS INC (TRBN)
Trubion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of protein therapeutic product candidates for the treatment of autoimmune diseases and cancer. Its product candidates include single-chain polypeptide proteins called small modular immunopharmaceuticals (SMIP) that are intended to bind to a specified target cell and elicit specific biological activity in a targeted disease state. The company's principal product candidate is TRU-015, which is in Phase IIb clinical trial for the treatment of rheumatoid arthritis. Its TRU-016 product candidate is directed to CD37, an antigen that is present on B cells, for the treatment of patients with B-cell malignancies, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company, through its collaboration with Wyeth, is also developing TRU-015 for use in multiple indications, such as systemic lupus erythematosus, and B-cell malignancies. Trubion Pharmaceuticals has a strategic collaboration with Wyeth for the development and worldwide commercialization of TRU-015 and other SMIP drug candidates. The company was founded in 1999. It was formerly known as Genecraft, LLC and changed its name to Trubion Pharmaceuticals, Inc. in 2003. Trubion Pharmaceuticals is headquartered in Seattle, Washington.
ALTUS PHARMACEUTICALS INC (ALTU)
Altus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of oral and injectable protein therapeutics for gastrointestinal and metabolic disorders. The company's products include ALTU-135, a Phase II completed clinical trial product is an orally-administered enzyme replacement therapy for the treatment of malabsorption due to exocrine pancreatic insufficiency; and ALTU-238, a Phase II completed clinical trial product is a crystallized formulation of human growth hormone (hGH) for the treatment of growth hormone deficiency in adults and hGH-related disorders. Its preclinical stage products comprise ALTU-237 for the treatment of hyperoxalurias and kidney stones; ALTU-236, which is designed to reduce the long-term effects associated with excess levels of phenylalanine; and ALTU-242 that is designed to reduce the long-term effects associated with excess levels of urate. The company has strategic alliance with Cystic Fibrosis Foundation Therapeutics, Inc. for the development of ALTU-135, as well as collaboration agreement with Genentech, Inc. to develop, manufacture, and commercializes ALTU-238; and Dr. Falk Pharma GmbH for commercializing ALTU-135 in Europe, the countries of the former Soviet Union, Israel, and Egypt. Altus Pharmaceuticals was incorporated in 1992. It was formerly known as Altus Biologics, Inc. and changed its name to Altus Pharmaceuticals, Inc. in 2004. The company is based in Cambridge, Massachusetts.
Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain management. It has two products in clinical development, which include Zingo and 4975. Zingo is an anesthetic that has completed two Phase 3 trials in the pediatric population for the treatment of pain associated with venipuncture and cannulation; and 4975 is an anesthetic for the treatment of site-specific moderate to severe pain, and is in multiple Phase 2 and Phase 3 trials in post-surgical and musculoskeletal pain. The company was incorporated in 2001. It was formerly known as Corgentech, Inc. and changed its name to Anesiva, Inc. in 2006. Anesiva is headquartered in South San Francisco, California.
GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutics for the treatment of cancer, heart disease, and vision loss. Its products include TNFerade, which is in the randomized, controlled portion of a Phase II trial for the treatment of locally advanced pancreatic cancer; BIOBYPASS, which is in a Phase II trial for the treatment of coronary artery disease; PEDF, which is in a Phase IB trial for the treatment of wet age-related macular degeneration, a leading cause of blindness in individuals over the age of 50; and cell transplantation therapy, which is in Phase I trials for the treatment of congestive heart failure. GenVec has collaborations with the Cordis Corporation; Terumo Corporation; Fuso Pharmaceuticals Industries, Ltd.; Warner-Lambert Company; Vaccine Research Center at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and with the U.S. Naval Medical Research Center. The company was incorporated in 1992 and is headquartered in Gaithersburg, Maryland.
OXiGENE, Inc. engages in the research and development of products for the treatment of cancer and certain eye diseases. The company focuses on the development of products for application as direct cancer treatment agents, particularly vascular targeting agents (VTAs). It also investigates the use of certain products in the field of ophthalmology, in particular age-related macular degeneration and myopic macular degeneration. The company's technology, Combretastatin, is a family of proprietary small molecule anti-tumor VTAs. OXiGENE's CA4P compound targets the inner areas of the tumor. It is developing OXi4503 that targets blood vessels at the central core of the tumor, and appears to affect the vessels and tumor cells at the periphery. The CA4P is being tested in five human clinical trials in oncology, and one human clinical trial in ophthalmology. It is in Phase I/II combination clinical trial with Carboplatin and Paclitaxel in advanced ovarian cancer. In addition, a Phase II single agent trial in advanced and metastatic anaplastic thyroid carcinoma (ATC), and a Phase I/II combination trial in newly diagnosed ATC. OXiGENE is undertaking a Phase I/II combination trial with radiotherapy in head and neck, lung, and prostate cancers, as well as a Phase Ib combination trial with a monoclonal antibody in colorectal cancer. Its anti-tumor agent, OXi6197, reduces blood flow in newly formed tumor vasculature. The company is conducting Phase II single agent trial to treat a form of thyroid cancer, anaplastic thyroid carcinoma and a Phase II study for ATC to evaluate the mean survival time of patients. It is undertaking a Phase Ib study to evaluate the combination of CA4P with the radiolabeled anti-CEA monoclonal antibody A5B7. Additionally, the company has Phase I/II clinical trial for the nonlife threatening ocular disease, wet age-related macular degeneration. OXiGENE was incorporated in 1988 and is headquartered in Waltham, Massachusetts.
CYTOKINETICS INCORPORATED (CYTK)
Cytokinetics Incorporated, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule drugs that specifically target the cytoskeleton. Cytoskeleton is a diverse, multi-protein framework that carries out fundamental mechanical activities of cells including mitosis, or the division of genetic material during cell division, intracellular transport, cell movement and contraction, and overall cell organization. The company's focus on the cytoskeleton enables it to develop novel drugs for cancer, cardiovascular, fungal, and other diseases. It has two drug candidates, SB-715992 and SB-743921, which are in the phase-1 and phase-2 clinical trial, and a novel drug candidate for the treatment of congestive heart failure. Cytokinetics has strategic alliances with GlaxoSmithKline and AstraZeneca AB. The company was co-founded by Ronald D. Vale, Lawrence S. B. Goldstein, and James A. Spudich in 1997. Cytokinetics is headquartered in San Francisco, California.
MANNKIND CORPORATION (MNKD)
MannKind Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for diseases, such as diabetes and cancer. It commenced phase three clinical trials in Europe of its lead product, the Technosphere insulin system, to treat diabetes. This therapy consists of a dry powder Technosphere formulation of insulin that is inhaled into the deep lung using MedTone inhaler. Its technology is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. The company was incorporated in 1991 as Pharmaceutical Discovery Corporation and changed its name to MannKind Corporation in 2001. MannKind Corporation is headquartered in Valencia, California.
EMERGENT BIOSOLUTIONS INC (EBS)
Emergent BioSolutions, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of immunobiotics primarily in the United States. Immunobiotics are pharmaceutical products, such as vaccines and immune globulins that assist the body's immune system to prevent diseases. The company operates in two segments, Biodefense and Commercial. The Biodefense segment develops, manufactures, and commercializes immunobiotics for use against biological agents. This segment's primary product is BioThrax, a vaccine for the prevention of anthrax infection. Its other products, which are in preclinical stage comprise Anthrax immune globulin, for post-exposure treatment of anthrax infection; Botulinum immune globulin for post-exposure treatment of illness caused by botulinum toxin; and Recombinant bivalent botulinum vaccine, a prophylaxis for illness caused by botulinum toxin. The Commercial segment develops immunobiotics for use against infectious diseases. This segment's product portfolio includes Typhoid vaccine, a single-dose vaccine in phase II clinical development; Hepatitis B therapeutic vaccine, for treating chronic carriers of hepatitis B infection, which is in phase II clinical development; and Group B streptococcus vaccine, a product in phase I clinical trial for administration to women of childbearing age for protection of the fetus and newborn babies. In addition, Emergent BioSolutions is developing a chlamydia vaccine and a meningitis B vaccine, which are in preclinical development. The company serves primarily the U.S. Department of Defense and the U.S. Department of Health and Human Services. It has collaboration agreements with U.K. Health Protection Agency for the development of a human botulinum immune globulin candidate; and with Sanofi Pasteur for the development of meningitis B vaccine candidate. The company, formerly known as BioPort Corporation, was founded in 1998 and is based in Rockville, Maryland.
ZIOPHARM ONCOLOGY INC (ZIOP)
ZIOPHARM Oncology, Inc., a biopharmaceutical company, engages in the development and commercialization of a portfolio of in-licensed cancer drugs. It focuses primarily on the licensing and development of proprietary drug candidate families that are related to cancer therapeutics that are already on the market or in development. The company's product candidates include ZIO-101, ZIO-201, and ZIO-301, which are in phase I and/or II studies. ZIO-101, organic arsenic is in a phase I/II trial in patients with advanced myeloma, as well as a phase I trial in advanced cancers; ZIO-201, stabilized isophosphoramide mustard is in a phase I/II trial in patients with advanced sarcoma, as well as in a phase I trials in advanced cancers; and ZIO-301, an anti-cancer agent that targets mitosis like the taxanes is in a phase I trial. ZIOPHARM was founded in 2003 and is based in New York, New York.
Bionovo, Inc. engages in the discovery and development of drugs in the areas of cancer and women's health primarily in the United States. It develops drugs to treat breast and ovarian cancers, and for menopause. The company's product and drug pipeline includes MF101, a selective estrogen receptor beta agonist, which is in Phase II trial to alleviate the symptoms of menopause, including hot flashes, night sweats, and bone mineral loss; and BZL101, an apoptosis inducing factor translocator/activator, which completed Phase I clinical trial, is an anticancer agent for breast, pancreatic, and ovarian cancers, and used for the treatment of other solid tumors. Its preclinical drug pipeline includes AA102, an apoptosis inducer, which would be used as an anticancer agent that attenuates mitochodrial membrane potential to cause a cytochrome c release and caspase activation to induce apoptosis; and VG101, an intra-vaginal gel for the treatment of postmenopausal vaginal dryness. The company has collaboration with the University of California at San Francisco; University of California at Berkeley; University of California at Davis; University of Texas, Southwestern; and University of Colorado Health Sciences College. Bionovo was founded in 2002 and is headquartered in Emeryville, California.
QLT, Inc., a bio-pharmaceutical company, engages in the discovery, development, and commercialization of therapies in the fields of ophthalmology, dermatology, oncology, and urology primarily in North America. The company's products include Visudyne, which is used for the treatment of choroidal neovascularization; and Eligard products that are used for prostate cancer incorporate a leutinizing hormone-releasing hormone agonist, or LHRH agonist, known as leuprolide acetate with its proprietary Atrigel drug delivery system. QLT also offers generic dermatology products, including lidocaine and prilocaine cream, erythromycin and benzoyl peroxide topical gel, mometasone furoate ointment, betamethasone dipropionate cream, and fluticasone propionate cream. In addition, it provides dental products, which include Atridox and Atrisorb-D. The company has strategic alliances with Novartis Ophthalmics. QLT was formed in 1981 and is headquartered in Vancouver, Canada.
METABASIS THERAPEUTICS INC (MBRX)
Metabasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs principally to treat metabolic diseases, cancer, and certain other diseases linked to pathways in the liver. It has three product candidates in clinical development, including CS-917, a product candidate for the treatment of type 2 diabetes; Pradefovir mesylate, a product candidate for the treatment of hepatitis B that is in phase II clinical trials; and MB07133, a product candidate for the treatment of primary liver cancer that is in a phase I clinical trial. The company has strategic alliances with Sankyo Company, Ltd.; Valeant Pharmaceuticals International; Merck & Co., Inc.; and Sicor, Inc. Metabasis Therapeutics was founded by Paul K. Laikind, Mark D. Erion, and John W. Beck in 1997. The company is headquartered in San Diego, California.
PROGEN PHARMACEUTICALS LIMITED (PGLA)
No description available.
StemCells, Inc., a biotechnology company, engages in the discovery, development, and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver, and pancreas. It develops therapies that use stem and progenitor cells to treat human diseases and injuries, such as neurodegenerative diseases, including Batten's, Parkinson's, and Alzheimer's diseases, and other metabolic genetic disorders. The company also develops its products for demyelinating disorders, including spinal cord injuries, stroke, hepatitis, chronic liver failure, and diabetes; and multiple sclerosis. StemCells is headquartered in Palo Alto, California.
ANADYS PHARMACEUTICALS INC (ANDS)
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing small molecule medicines for the treatment of hepatitis C virus (HCV), hepatitis B virus (HBV), and certain bacterial infections. The company's primary clinical development programs include ANA975, an oral prodrug of isatoribine for the treatment of HCV and HBV, and ANA380 for the treatment of HBV. ANA975, which is in phase I clinical trails, is a proprietary chemical entity that is administered orally and then is converted into the active compound, resulting in isatoribine in the bloodstream. ANA380 is in phase II clinical trails in patients with lamivudine-resistant, or lamR, hepatitis B virus. The company also has discovery programs exploring the use of oral prodrugs of TLR-7 agonists and direct antiviral discovery efforts focused on structural-based drug design. In addition, it develops a class of molecules that act against certain bacterial infections, including hospital-based infections, by inhibiting ribosomal function, which is the ability to synthesize new proteins. Anadys Pharmaceuticals has collaborative agreements with Amgen, Inc. and Daiichi Pharmaceutical Co. Ltd. to discover compounds against therapeutic targets of Amgen and Daiichi; and with Aphoenix, Inc. to discover and advance compounds against Aphoenix targets for multiple therapeutic indications. The company was incorporated in 1992 under the name ScripTech Pharmaceuticals, Inc. It changed its name to Scriptgen Pharmaceuticals, Inc. in 1994 and to Anadys Pharmaceuticals, Inc. in 2000. Anadys Pharmaceuticals is headquartered in San Diego, California.
HOLLIS-EDEN PHARMACEUTICALS INC (HEPH)
Hollis-Eden Pharmaceuticals, Inc., a development stage pharmaceutical company, engages in the discovery, development, and commercialization of products, for the treatment of diseases and disorders, in which the body is unable to mount an appropriate immune response. The company's development efforts focus on radiation and chemotherapy induced immune suppression and immune dysregulation caused by infectious diseases, such as HIV, malaria, and tuberculosis. In addition, Hollis-Eden Pharmaceuticals is developing a nonimmune regulating hormone drug candidate for providing protection against DNA mutations from radiation exposure and chemotherapy treatment. The company was founded in 1992. It was formerly known as Initial Acquisition Corp and changed its name to Hollis-Eden Pharmaceuticals, Inc. in 1997. Hollis-Eden Pharmaceuticals is headquartered in San Diego, California.
CORNERSTONE THERAPEUTICS INC (CRTX)
Critical Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products to treat respiratory, inflammatory, and critical care diseases. The company's primary product is Zyflo Filmtab, a tablet formulation of zileuton for the prevention and chronic treatment of asthma. Its products under development include Zileuton, through development of additional formulations, controlled-release formulation and an intravenous formulation; CTI-01, a small molecule product candidate for patients who are at high risk for post-surgical complications following cardiopulmonary bypass; HMGB1, a cytokine, for the development of products to treat inflammation-mediated diseases; and Alpha-7, a small molecules designed to inhibit the body's inflammatory response by acting on the nicotinic alpha-7 cholinergic target. Critical Therapeutics has strategic collaboration with MedImmune, Inc. and Beckman Coulter, Inc. The company was co-founded by Mitchell Fink, Kevin Tracey, and H. Shaw Warren. Critical Therapeutics was incorporated in 2000 as Medicept, Inc. and changed its name to Critical Therapeutics, Inc. in 2001. The company is headquartered in Lexington, Massachusetts.
OPEXA THERAPEUTICS INC (OPXA)
Opexa Therapeutics, Inc., a development stage biopharmaceutical company, develops autologous cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, diabetes, and cardiovascular diseases. Its therapies are based on the company's T-cell and adult stem cell technologies. The company's lead product, Tovaxin is a T-cell-based therapeutic vaccine for multiple sclerosis, which is in Phase IIb clinical trials to treat the disease by inducing an immune response against the autoimmune myelin peptide-reactive T-cells. Opexa Therapeutics also holds a license for T-cell vaccination technology for rheumatoid arthritis, which allows the isolation of pathogenic T-cells from synovial fluid drawn from a patient, as well as holds a license to a stem technology, which enables production of adult multipotent stem cells from mononuclear cells of peripheral blood for use in autologous therapy. It engages in preclinical development of stem cell therapy for indications in diabetes mellitus. The company was founded in 2003. It was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in 2006. Opexa Therapeutics is based in the Woodlands, Texas.
MediciNova, Inc., a biopharmaceutical company, engages in the acquisition and development of small molecule therapeutics worldwide. The company's clinical products under development include MN-001 for the treatment of bronchial asthma, which is in Phase III clinical program; MN-221 for the treatment of status asthmaticus, which is in Phase II clinical trial; MN-166 for the treatment of multiple sclerosis that is in a two year randomized, double-blind, placebo-controlled multi-center Phase II clinical trial; and MN-001 for the treatment of interstitial cystitis, which completed a Phase II/III clinical trial. It also develops MN-029 for the treatment of solid tumors, which completed Phase I clinical trial; MN-305 for the treatment of generalized anxiety disorder, which completed a Phase II/III clinical trial; MN-305 for the treatment of insomnia that is in Phase II clinical trial; and MN-221 for the treatment of preterm labor, which is in Phase Ib clinical study. In addition, the company develops MN-246 for the treatment of urinary incontinence, which completed a double-blind, randomized, placebo-controlled, single escalating dose Phase I clinical trial; MN-447 for the treatment of thrombotic disorders, which is in preclinical development stage; and MN-462 for the treatment of thrombotic disorders, which is in preclinical development stage. MediciNova, Inc. has strategic alliances with Kissei Pharmaceutical Co, Ltd.; Kyorin Pharmaceutical; Mitsubishi Pharma Corporation; Meiji Seika Kaisha, Ltd.; and Angiogene Pharmaceuticals, Ltd. The company was founded in 2000 and is headquartered in San Diego, California.
PROTALIX BIOTHERAPEUTICS INC (PLX)
Protalix BioTherapeutics, Inc., a development stage company, engages in developing and producing recombinant therapeutic proteins that are expressed through its plant cell system in the United States. Its principal product candidate, prGCD, is a proprietary plant cell expressed recombinant Glucocerebrosidase enzyme-based protein for the treatment of Gaucher Disease. The company is also developing PRX-102, a proprietary alpha Galactosidase enzyme for the treatment of Fabry disease, a genetic lysosomal storage disorder in humans, the symptoms of which involve the accumulation of lipids in the cells of the kidneys, heart, and other organs; and PRX-111, a human fertility hormone targeted at the infertility market. In addition, it is developing a proprietary plant-based acetylcholinestrase and its molecular variants for use in various therapeutic and prophylactic indications, including a Biodefense program; and an oral platform for delivering active recombinant proteins systematically through enteral administration through the oral administration of transgenic plant cells. Protalix BioTherapeutics has strategic collaboration with Teva Pharmaceutical Industries, Ltd. for the development and manufacturing of two proteins using the company's plant cell expression system; and Yeda Research and Development Company Limited to design Glucocerebrosidase for the treatment of Gaucher Disease, as well as a licensing agreement with Icon Genetics AG to license Icon's amplification technology for utilization in the expression of its products. The company was founded in 1993 and is based in Carmiel, Israel.
SUNESIS PHARMACEUTICALS INC (SNSS)
Sunesis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for use in oncology and various medical needs. It offers fragment based discovery approach, Tethering, which is a process whereby a target protein known to be involved in a disease process is engineered to facilitate the binding of small drug fragments. The company's proprietary oncology products are SNS-595, a cell-cycle inhibitor representing anti-tumor drugs, which is in Phase II clinical trial in small cell lung cancer, Phase II clinical trial in ovarian cancer, and Phase II clinical trial in acute leukemias; SNS-032, a targeted inhibitor of cyclin-dependent kinases, which is in Phase I clinical trial in patients with advanced solid tumors, and Phase I clinical trial in patients with advanced B-cell lymphoid malignancies; and SNS-314, a targeted inhibitor of the Aurora A, B, and C kinases for the treatment of cancer. It also provides Raf kinase inhibitors program in strategic collaboration with Biogen Idec, Inc.; and small molecule leads that inhibit oncology and immunology kinase targets. In addition, the company offers Cathepsin S inhibitors program for inflammatory diseases in strategic collaboration with Johnson & Johnson Pharmaceutical Research and Development, L.L.C.; and BACE inhibitors for Alzheimer's disease and anti-viral inhibitors program in strategic collaboration with Merck & Co., Inc. Sunesis Pharmaceuticals was founded in 1998 as Mosaic Pharmaceuticals, Inc. and subsequently changed its name to Sunesis Pharmaceuticals, Inc. The company is headquartered in South San Francisco, California.
PLURISTEM THERAPEUTICS INC (PSTI)
Per-Se Technologies, Inc. offers connective healthcare solutions to physicians and hospitals in the United States. It operates through two divisions, Physician Services and Hospital Services. The Physician Services division provides business management outsourcing services to hospital-affiliated physician practice groups, physicians groups in academic settings, and other large physician practices. Its services include clinical data collection, data input, medical coding, billing, contract management, cash collections, accounts receivable management, and reporting of metrics related to the physician practice. The division also offers a physician practice management solution that is delivered through an application service provider model. The Hospital Services division delivers electronic and Internet-based business-to-business solutions that focus on electronic processing of medical transactions, as well as complementary transactions, such as electronic remittance advices, realtime eligibility verification, and print and mail services. Its other solutions include denial management, staff scheduling solutions, and patient scheduling solutions. The company markets its products and services primarily to hospital-affiliated physician practices, physician groups in academic settings, hospitals, and integrated delivery networks. Per-Se Technologies was founded in 1985 and is headquartered in Alpharetta, Georgia.
VANDA PHARMACEUTICALS INC (VNDA)
Vanda Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of clinical-stage drug candidates for various central nervous system disorders. It offers iloperidone, a compound for the treatment of schizophrenia and bipolar disorder; and VEC-162, a compound for the treatment of sleep and mood disorders. The company also provides VSF-173, a compound for the treatment of excessive sleepiness. Vanda Pharmaceuticals was founded in 2002 and is headquartered in Rockville, Maryland.
NEUROBIOLOGICAL TECHNOLOGIES INC (NTII)
Neurobiological Technologies, Inc., a biotechnology company, engages in the acquisition and development of central nervous system related drug candidates. It focuses on therapies for neurological conditions that occur in connection with dementia, alzheimer's disease, ischemic stroke, neuropathic pain, and brain cancer. Neurobiological Technologies offers Memantine an orally dosed compound used for the treatment of alzheimer's disease and neuropathic pain in the United States and Europe. The company also develops Viprinex, which is a late-stage reperfusion therapy for use in the treatment of acute ischemic stroke. Neurobiological Technologies has a strategic research and marketing cooperation agreement with Merz Pharmaceuticals GmbH and Children's Medical Center Corporation to further the clinical development and commercialization of Memantine. The company was founded by Enoch Callaway and John B. Stuppin in 1987. Neurobiological Technologies is based in Emeryville, California.
|
